My portfolio investments and their news

Stock Detailsmeta:

version: v1.0

status: 200

copywrite: https://apicalls.io

symbol: Quotes Data

processedTime: 2025-01-12T05:03:26.241553Z

body:

- Item 1:

preMarketChange: None

preMarketChangePercent: None

preMarketPrice: None

preMarketTime: None

postMarketChange: 0.179993

postMarketChangePercent: 0.0759944

postMarketPrice: 237.03

postMarketTime: 1736557190

language: en-US

region: US

quoteType: EQUITY

typeDisp: Equity

quoteSourceName: Nasdaq Real Time Price

triggerable: True

customPriceAlertConfidence: HIGH

currency: USD

esgPopulated: False

marketState: CLOSED

hasPrePostMarketData: True

firstTradeDateMilliseconds: 345479400000

priceHint: 2

regularMarketChange: -5.849991

regularMarketDayHigh: 240.15

regularMarketDayRange: 233.0 - 240.15

regularMarketDayLow: 233

regularMarketVolume: 58293813

regularMarketPreviousClose: 242.7

bid: 223.29

ask: 247.42

bidSize: 1

askSize: 1

fullExchangeName: NasdaqGS

financialCurrency: USD

regularMarketOpen: 240.025

averageDailyVolume3Month: 45067829

averageDailyVolume10Day: 42582530

fiftyTwoWeekLowChange: 72.770004

fiftyTwoWeekLowChangePercent: 0.4435032

fiftyTwoWeekRange: 164.08 - 260.1

fiftyTwoWeekHighChange: -23.25

fiftyTwoWeekHighChangePercent: -0.08938869

fiftyTwoWeekLow: 164.08

fiftyTwoWeekHigh: 260.1

fiftyTwoWeekChangePercent: 28.982199

dividendDate: 1731542400

earningsTimestamp: 1738270800

earningsTimestampStart: 1738270800

earningsTimestampEnd: 1738270800

earningsCallTimestampStart: 1738274400

earningsCallTimestampEnd: 1738274400

isEarningsDateEstimate: False

trailingAnnualDividendRate: 0.98

trailingPE: 38.891624

dividendRate: 1

trailingAnnualDividendYield: 0.004037907

dividendYield: 0.42

epsTrailingTwelveMonths: 6.09

epsForward: 8.31

epsCurrentYear: 7.39695

priceEpsCurrentYear: 32.019955

sharesOutstanding: 15115799552

bookValue: 3.767

fiftyDayAverage: 238.7128

fiftyDayAverageChange: -1.862793

shortName: Apple Inc.

longName: Apple Inc.

regularMarketChangePercent: -2.4103794

regularMarketPrice: 236.85

corporateActions:

regularMarketTime: 1736542802

exchange: NMS

messageBoardId: finmb_24937

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

fiftyDayAverageChangePercent: -0.00780349

twoHundredDayAverage: 215.46355

twoHundredDayAverageChange: 21.38646

twoHundredDayAverageChangePercent: 0.0992579

marketCap: 3580177154048

forwardPE: 28.501804

priceToBook: 62.87497

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 1.9 - Buy

tradeable: False

cryptoTradeable: False

displayName: Apple

symbol: AAPL

nstock news

Published: 2025-01-11 20:31:13 ET

AAPL

(Reuters) - Apple's board of directors recommended investors vote against a shareholder proposal to abolish the company's Diversity, Equity, and Inclusion (DEI) programs, according to a proxy filing from the company.

The National Center for Public Policy, a conservative think tank, submitted a proposal that the company consider abolishing its "Inclusion & Diversity program, policies, department and goals."

The proposal cited recent Supreme Court decisions, and made the argument that DEI poses "litigation, reputational and financial risks to companies" and could make Apple more vulnerable to lawsuits.

Apple responded that it had a well-established compliance program and the proposal was unnecessary. It added that the shareholder proposal was an inappropriate attempt to micromanage Apple's business strategy.

"Apple is an equal opportunity employer and does not discriminate in recruiting, hiring, training, or promoting on any basis protected by law", the iPhone maker said in the filing. The news was first reported by TechCrunch.

Several major companies including Meta and Amazon are winding down diversity programs ahead of Republican Donald Trump's return to the U.S. presidency as conservative opposition to such initiatives grows louder.

Conservative groups have denounced DEI programs and threatened to sue companies over them, emboldened by a U.S. Supreme Court ruling in 2023 that struck down affirmative action in university admissions decisions.

The changes show how some of America's biggest businesses have reacted to a larger conservative backlash against diversity initiatives, which multiplied after widespread protests following the police killings of George Floyd and other Black Americans in 2020.

(Reporting by Chandni Shah in Bengaluru)nstock news

Vladimir Zakharov

Vladimir Zakharov

Friends, each week I set out to research and write the best, most informative, most actionable article I can deliver to my fellow dividend investors.

I'm aware of the magnitude of content on the Internet geared to

If you want access to our entire Portfolio and all our current Top Picks, feel free to join us for a 2-week free trial at High Yield Landlord.

We are the largest real estate investment community on Seeking Alpha with over 2,000 members on board and a perfect 5/5 rating from 400+ reviews:

For a Limited Time - You can join us at a deeply reduced rate!

Start Your 2-Week Free Trial Today!

This article was written by

Austin Rogers is a REIT specialist with a professional background in commercial real estate. He writes about high-quality dividend growth stocks with the goal of generating the safest growing passive income stream possible. Since his ideal holding period is "lifelong," his focus is on portfolio income growth rather than total returns.

Analystâ€™s Disclosure: I/we have a beneficial long position in the shares of ADC, AMH, AMT, ARTNA, CTRE, EGP, HASI, MAA, NEE, REXR, VICI, WTRG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Dilok Klaisataporn/iStock via Getty Images

Dilok Klaisataporn/iStock via Getty Images

To earn a decent income from your savings has been a challenge for retirees for the past two decades. For almost a decade, the interest rates remained either zero or near zero. Only recently, in the last couple

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. This includes two High-Income portfolios, two DGI portfolios, and a conservative NPP strategy portfolio with low drawdowns and high growth. For more details or a two-week free trial, please click here.

This article was written by

Financially Free Investor is a financial writer with 25 years investment experience. He focuses on investing in dividend-growing stocks with a long-term horizon. He applies a unique 3-basket investment approach that aims for 30% lower drawdowns, 6% current income, and market-beating growth on a long-term basis and he focuses on dividend-growing stocks with a long-term horizon.

Analystâ€™s Disclosure: I/we have a beneficial long position in the shares of ABT, ABBV, CI, JNJ, PFE, NVS, NVO, AZN, UNH, CL, CLX, UL, NSRGY, PG, TSN, ADM, BTI, MO, PM, KO, PEP, EXC, D, DEA, DEO, ENB, MCD, BAC, PRU, UPS, WMT, WBA, CVS, LOW, AAPL, IBM, CSCO, MSFT, INTC, T, VZ, CVX, XOM, VLO, ABB, ITW, MMM, LMT, LYB, RIO, O, NNN, WPC, ARCC, ARDC, AWF, CII, CHI, DNP, PEO, USA, UTF, UTG, RFI, RNP, RQI, EVT, EOS, FFC, GOF, TLT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: The information presented in this article is for informational purposes only and in no way should be construed as financial advice or recommendation to buy or sell any stock. The author is not a financial advisor. Please always do further research and do your own due diligence before making any investments. Every effort has been made to present the data/information accurately; however, the author does not claim 100% accuracy. The stock portfolios presented here are model portfolios for demonstration purposes. For the complete list of our LONG positions, please see our profile on Seeking Alpha.

Published: 2025-01-11 06:08:41 ET

AAPL

WASHINGTON (Reuters) - The lawyer for TikTok and its Chinese parent company ByteDance offered a warning during Supreme Court arguments over a law that would compel the sale of the short-video app or ban it in the United States: If Congress could do this to TikTok, it could come after other companies, too.

The law, which was the subject of arguments before the nine justices on Friday, sets a Jan. 19 deadline for ByteDance to sell the popular social media platform or face a ban on national security grounds. The companies have sought, at the very least, a delay in implementation of the law, which they say violates the U.S. Constitution's First Amendment protection against government abridgment of free speech.

Noel Francisco, representing TikTok and ByteDance, argued that Supreme Court endorsement of this law could enable statutes targeting other companies on similar grounds.

"AMC movie theaters used to be owned by a Chinese company. Under this theory, Congress could order AMC movie theaters to censor any movies that Congress doesn't like or promote any movies that Congress wanted," Francisco told the justices.

The justices signaled through their questions during the arguments that they were inclined to uphold the law, although some expressed serious concerns about its First Amendment implications.

TikTok is a platform used by about 170 million people in the United States, roughly half the country's population. Congress passed the measure last year with overwhelming bipartisan support, as lawmakers cited the risk of the Chinese government exploiting TikTok to spy on Americans and carry out covert influence operations.

Jeffrey Fisher, the lawyer representing TikTok content creators who also have challenged the law, noted during the Supreme Court arguments that Congress with this measure was focusing on TikTok and not major Chinese online retailers including Temu.

"Would a Congress (that is) really worried about these very dramatic risks leave out an e-commerce site like Temu that has 70 million Americans using it?" Fisher asked. "It's very curious why you just single out TikTok alone and not other companies with tens of millions of people having their own data taken, you know, in the process of engaging with those websites and equally, if not more, available to Chinese control."

Democratic President Joe Biden signed the measure into law and his administration is defending it in this case. The deadline for divestiture is just one day before Republican Donald Trump, who opposes the ban, takes office as Biden's successor.

'FOREIGN ADVERSARIES'

Solicitor General Elizabeth Prelogar, arguing for the Biden administration in defending the law, said it was crucial that it take effect on Jan. 19 as scheduled in order to force ByteDance to act on divestiture.

"Foreign adversaries do not willingly give up their control over this mass communications channel in the United States," Prelogar said.

"When push comes to shove, and these restrictions take effect, I think it will fundamentally change the landscape with respect to what ByteDance is willing to consider. And it might be just the jolt that Congress expected the company would need to actually move forward with the divestiture process," Prelogar said.

If the ban takes affect on Jan. 19, Apple and Alphabet's Google would no longer be able to offer

TikTok for downloads for new users but existing users could still access the app. The U.S. government and TikTok agree that app would degrade and eventually become unusable over time because companies would not be able to offer supporting services.

The Supreme Court also debated whether the possibility of TikTok being used for covert influence campaigns or propaganda purposes by China justified the banning it.

"Look, everybody manipulates content," Francisco told the court. "There are lots of people who think CNN, Fox News, the Wall Street Journal, the New York Times are manipulating their content. That is core protected speech."

Trump on Dec. 27 urged the court to put a hold on the Jan. 19 deadline to give his incoming administration "the opportunity to pursue a political resolution of the questions at issue in the case."

Under the law, the U.S. president has the power to extend the Jan. 19 deadline for 90 days, but under circumstances that do not appear to apply to the current situation in which ByteDance has made no apparent effort to sell TikTok's U.S. assets. The law mandates that the president certify that significant progress has been made toward a sale, with binding legal agreements.

Regardless, Trump does not become president until after the deadline - though Francisco said "we might be in a different world" once Trump is back in the White House.

Justice Brett Kavanaugh asked Prelogar whether the president could "say that we're not going to enforce this law?"

"I think as a general matter, of course the president has enforcement discretion," Prelogar said.

"Again, that's one of the reasons why I think it makes perfect sense to issue a preliminary injunction here and simply buy everybody a little breathing space," Francisco said.

(Reporting by David Shepardson; Editing by Will Dunham)

By David Shepardsonnstock news

Error fetching the URL: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4748878-xlg-outperforms-the-s-and-p500-indexnstock news

We are experiencing some temporary issues. The market data on this page is currently delayed.

Please bear with us as we address this and restore your personalized lists.

(Bloomberg) -- Apple Inc. disclosed a 18% pay increase for Chief Executive Officer Tim Cook ahead of its annual meeting next month, while also saying it opposed a shareholder measure calling for an end to the companys diversity program.

Cooks compensation grew to $74.6 million in 2024, compared with $63.2 million the prior year, Apple said in its annual proxy filing on Friday. In addition to executive compensation, investors will vote on four outside proposal at the meeting on Feb. 25. The company opposed all of them.

The measure about Apples diversity, equity and inclusion, or DEI, efforts urged the company to consider abolishing the program because it may discriminate against employees and draw lawsuits. The company said the proposal was an inappropriate attempt to restrict Apples business operations and that it already assesses legal and regulatory risks.

Cooks pay was made up of a $3 million base salary, $58.1 million in stock awards, and roughly $13.5 million in additional compensation. The raise mostly comes from an increase in stock award value.

While Cooks pay is up significantly from last year, its still a far cry from his total compensation in 2022, which reached nearly $100 million thanks to stock awards. His pay was cut at his discretion in 2023 after pushback from employees and shareholders.

Apples board of directors said it made no changes to the amount or structure of Mr. Cooks 2025 total target compensation.

Other executives, including Apples retail chief, former chief financial officer, chief operating officer and general counsel, all made more than $27 million in 2024, representing slight increases from the prior year. Luca Maestri, the ex-CFO, was recently replaced as by Kevan Parekh.

Most Read from Bloomberg Businessweek

He Built Russias Biggest Tech Company. Now Hes Starting OverWithout Putin

The US Government Is Sitting on a Possible Solution to the Housing Crisis

What Happens When TikToks Trend Machine Shuts Down?

Musk Tries to Pick a Fight with the UK

Israels Wartime Farmers Are Relearning How to Plow Without GPS

Sign in to access your portfolionstock news

Error fetching the URL: 404 Client Error: Not Found for url: https://finance.yahoo.com/m/f8950c0e-7669-39cd-9e7d-be81d3956c93/hershey-ceo-michele-buck-to.htmlnstock news

Error fetching the URL: 404 Client Error: Not Found for url: https://finance.yahoo.com/m/7d026465-47c7-3f98-8601-7e2ab779425f/funds-bet-on-apple%2C-google.htmlnstock news

The clock is ticking for TikTok. The Chinese-owned video-sharing platform used by nearly half the country could disappear from U.S. app stores later this month under a new security law. On Friday, TikTok argued its case before the Supreme Court.

Sign in to access your portfolionstock news

If sentiment is anything to go by, the Magnificent 7 stocks, led by Apple Nvidia and Microsoft are set to be replaced by a movie that may or may not be equally goodBATMMAAN. While cute names are fun to write about, theyre a lousy way to organize a stock portfolio. Think of it as the DC comics superhero spelled by a toddler.

Sign in to access your portfolio

Stock Detailsmeta:

  version: v1.0

  status: 200

copywrite: https://apicalls.io

symbol: Quotes Data

processedTime: 2025-01-12T05:04:01.836632Z

body:

- Item 1:

preMarketChange: None

preMarketChangePercent: None

preMarketPrice: None

preMarketTime: None

postMarketChange: -0.19998169

postMarketChangePercent: -0.042726565

postMarketPrice: 467.85

postMarketTime: 1736557200

language: en-US

region: US

quoteType: EQUITY

typeDisp: Equity

quoteSourceName: Delayed Quote

triggerable: True

customPriceAlertConfidence: HIGH

currency: USD

regularMarketTime: 1736542802

exchange: NYQ

messageBoardId: finmb_285827

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

esgPopulated: False

longName: Lockheed Martin Corporation

marketState: CLOSED

regularMarketChangePercent: -0.170634

regularMarketPrice: 468.05

corporateActions:

shortName: Lockheed Martin Corporation

dividendRate: 13.2

trailingAnnualDividendYield: 0.026874267

dividendYield: 2.82

epsTrailingTwelveMonths: 27.61

epsForward: 28.11

epsCurrentYear: 26.77688

priceEpsCurrentYear: 17.479631

sharesOutstanding: 237035008

bookValue: 30.508

fiftyDayAverage: 515.6688

fiftyDayAverageChange: -47.618835

fiftyDayAverageChangePercent: -0.09234383

twoHundredDayAverage: 512.7632

twoHundredDayAverageChange: -44.713196

twoHundredDayAverageChangePercent: -0.08720048

marketCap: 110944231424

forwardPE: 16.650658

priceToBook: 15.341877

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 2.3 - Buy

tradeable: False

cryptoTradeable: False

hasPrePostMarketData: True

firstTradeDateMilliseconds: 221149800000

priceHint: 2

regularMarketChange: -0.800018

regularMarketDayHigh: 471.59

regularMarketDayRange: 465.73 - 471.59

regularMarketDayLow: 465.73

regularMarketVolume: 952664

regularMarketPreviousClose: 468.85

bid: 467.01

ask: 471.8

bidSize: 8

askSize: 18

fullExchangeName: NYSE

financialCurrency: USD

regularMarketOpen: 468

averageDailyVolume3Month: 1213218

averageDailyVolume10Day: 997440

fiftyTwoWeekLowChange: 54.129974

fiftyTwoWeekLowChangePercent: 0.13077399

fiftyTwoWeekRange: 413.92 - 618.95

fiftyTwoWeekHighChange: -150.90002

fiftyTwoWeekHighChangePercent: -0.24380001

fiftyTwoWeekLow: 413.92

fiftyTwoWeekHigh: 618.95

fiftyTwoWeekChangePercent: 2.2300363

dividendDate: 1735257600

earningsTimestamp: 1738071000

earningsTimestampStart: 1738071000

earningsTimestampEnd: 1738071000

earningsCallTimestampStart: 1738080000

earningsCallTimestampEnd: 1738080000

isEarningsDateEstimate: False

trailingAnnualDividendRate: 12.6

trailingPE: 16.95219

displayName: Lockheed Martin

symbol: LMT

nstock news

Sundry Photography

If you think technical analysis is silly, thanks for reading this far. Now, you might want to exit. I aim to educate, and when I see the charts speak to me as they are doing now for aerospace giant Lockheed Martin Corp. (

experience.Â

24/7 access to Sungardenâ€™s investment research deck

Bottom-line analysis of stocks, ETFs, and option strategies

Trade alerts and rationale, delivered in real-time

Proprietary educational content

You wonâ€™t get: sales pitches, outlandish claims, greed-driven speculation

This article was written by

Analystâ€™s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.nstock news

Dilok Klaisataporn/iStock via Getty Images

Dilok Klaisataporn/iStock via Getty Images

To earn a decent income from your savings has been a challenge for retirees for the past two decades. For almost a decade, the interest rates remained either zero or near zero. Only recently, in the last couple

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. This includes two High-Income portfolios, two DGI portfolios, and a conservative NPP strategy portfolio with low drawdowns and high growth. For more details or a two-week free trial, please click here.

This article was written by

Financially Free Investor is a financial writer with 25 years investment experience. He focuses on investing in dividend-growing stocks with a long-term horizon. He applies a unique 3-basket investment approach that aims for 30% lower drawdowns, 6% current income, and market-beating growth on a long-term basis and he focuses on dividend-growing stocks with a long-term horizon.

Analystâ€™s Disclosure: I/we have a beneficial long position in the shares of ABT, ABBV, CI, JNJ, PFE, NVS, NVO, AZN, UNH, CL, CLX, UL, NSRGY, PG, TSN, ADM, BTI, MO, PM, KO, PEP, EXC, D, DEA, DEO, ENB, MCD, BAC, PRU, UPS, WMT, WBA, CVS, LOW, AAPL, IBM, CSCO, MSFT, INTC, T, VZ, CVX, XOM, VLO, ABB, ITW, MMM, LMT, LYB, RIO, O, NNN, WPC, ARCC, ARDC, AWF, CII, CHI, DNP, PEO, USA, UTF, UTG, RFI, RNP, RQI, EVT, EOS, FFC, GOF, TLT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: The information presented in this article is for informational purposes only and in no way should be construed as financial advice or recommendation to buy or sell any stock. The author is not a financial advisor. Please always do further research and do your own due diligence before making any investments. Every effort has been made to present the data/information accurately; however, the author does not claim 100% accuracy. The stock portfolios presented here are model portfolios for demonstration purposes. For the complete list of our LONG positions, please see our profile on Seeking Alpha.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Lockheed Martin Corp.s LMT business unit, Aeronautics, recently clinched a modification contract for the F-35 fighter aircraft. The award has been offered by the Naval Air Systems Command, Patuxent River, MD.

Valued at $41.6 million, the contract is expected to be completed by March 2028. Per the terms of the deal, Lockheed will procure engineering, integration support, hardware, and installation support for flight test instrumentation modifications to F-35 production aircraft.

The majority of work related to this deal will be carried out in Fort Worth, TX.

Global defense spending has surged as nations strengthen their military capabilities, driving demand for advanced weaponry like fighter jets, which are essential for air combat. This trend has significantly benefited Lockheed, a leading manufacturer of combat aircraft, through steady orders from the Pentagon and U.S. allies.

Lockheeds F-35 fighter jet, renowned as the most advanced fifth-generation aircraft, stands out for its mission readiness and cutting-edge technology. Equipped with advanced sensors and communication systems, the F-35 seamlessly connects air, land, sea, space and cyber domains, enhancing situational awareness.

These exceptional features have fueled strong demand for this jet. As of Sept. 30, 2024, Lockheed had delivered 1,040 F-35 aircraft since the program's inception. The recent contract win underscores the sustained popularity of the F-35 in the global combat jet market, further solidifying its position as a cornerstone of modern air defense systems.

Rising military conflicts, terrorism and border disputes, along with rapid technological advancements in combat jets, have led nations to increase their defense spending on combat-proven jets, which constitute an integral part of their defense structure.

This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 3.7% for the global fighter aircraft market during the 2024-2029 period.

Such strong market prospects drive growth opportunities for Lockheed, backed by its robust portfolio of combat jets, including the F-16, F-22 and F-21 aircraft, in addition to the F-35 jet.

Other defense companies that are likely to benefit from the expanding global fighter aircraft market are discussed below.

Northrop Grumman Corporation NOC: It is a leading provider of manned and unmanned air systems. It builds some of the worlds most advanced aircraft, such as the E-2C Hawkeye 2000, A-10 Thunderbolt II, F-5 Tiger Fighter Jet and many more.

Northrop has a long-term (three to five years) earnings growth rate of 19%. The Zacks Consensus Estimate for NOCs 2025 sales indicates growth of 3.4% from the year-ago estimated figure.

Embraer ERJ: The company offers a comprehensive portfolio of the most advanced aircraft in the combat market, which includes the A-29 Super Tucano light attack and advanced trainer and the C-390 Millennium military multi-mission aircraft.

The Zacks Consensus Estimate for ERJs 2025 sales indicates growth of 18.3% from the prior-year estimated number. The stock boasts a solid average earnings surprise of 127.28% for the trailing four quarters.

Textron TXT: Its Textron Aviation Defense unit offers the largest and most successful flight training system in the world. Textron Aviation Defenses portfolio includes the Beechcraft AT-6E Wolverine jet, which covers a wide-mission spectrum including training, manned Intelligence Surveillance and Reconnaissance as well as light precision attack.

Textron has a long-term earnings growth rate of 10.1%. The Zacks Consensus Estimate for TXTs 2025 sales indicates growth of 7.4% from the year-ago estimated figure.

Shares of LMT have gained 1.7% in the past six months against the industrys 0.9% decline.

Image Source: Zacks Investment Research

LMT currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1

Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Lockheed Martin Corporation (LMT) : Free Stock Analysis Report

Northrop Grumman Corporation (NOC) : Free Stock Analysis Report

Embraer-Empresa Brasileira de Aeronautica (ERJ) : Free Stock Analysis Report

Textron Inc. (TXT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Sign in to access your portfolionstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

RTX Corporations RTX unit, Raytheon, recently secured a $333.3 million contract for facilitating the full-rate production of Standard Missile-6 (SM-6). RTX will also supply spares and a round design agent for SM-6 under this agreement.

The majority of the work related to this contract will be performed in Tucson, AZ, and Huntsville, AL. This contract is projected to be completed by October 2027.The award has been provided by the Naval Sea Systems Command, Washington, D.C. This contract includes options that, if exercised, will bring the total value of the agreement to $908.1 million.

With countries worldwide enhancing their defense capabilities, spending on advanced military arms and ammunition, including missiles and missile systems, has been rapidly increasing. RTX, as a prominent manufacturer of missile systems, has been benefiting from a steady flow of orders from the Pentagon and other U.S. allies. The recent contract is an example of that.RTX's SM-6 missile is an advanced and versatile defense system for naval ships. It can handle multiple missions, including defending against air attacks, surface threats and ballistic missiles, making it highly effective in protecting fleets. Its advanced design combines reliable technology to provide strong and cost-effective defense for the U.S. Navy and its allies.Such impressive features of this missile must have enabled the company to deliver more than 500 of SM-6 missiles to the U.S. Navy, which reflects the solid demand it enjoys in the missile market.

Rising military conflicts, terrorism and border disputes have led nations to increase their focus on national security, particularly on missile defense systems in recent times, backed by the rapid development of advanced missile technologies over the last decade.This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 5% for the global missiles and missile defense system market during the 2025-2030 period.Such massive growth projections offer a strategic advantage to RTX, which has a handful of combat-proven missiles in its product portfolio, like the TOW missile, Guidance Enhanced Missile, Advanced Medium Range Air-to-Air Missile, Tomahawk, Standard Missile 2 and a few more, in addition to the SM-6.

Other defense companies that are likely to enjoy the perks of the expanding missiles and missile system market have been discussed below:Northrop Grumman NOC: Northrop Grumman provides high-speed, long-range strike weapons like the AARGM-ER, which is a supersonic, air-launched tactical missile system. It also develops and builds advanced missile defense technology, ranging from command systems to directed energy weapons, advanced munitions and powerful sensors.The companys long-term (three to five years) earnings growth rate is 19%. The Zacks Consensus Estimate for NOCs 2025 sales indicates year-over-year growth of 3.4%.The Boeing Company BA: It manufactures various missile defense systems, including the Ground-based Midcourse Defense, Aegis Ballistic Missile Defense and Avenger. Boeing-built and supported air and missile defense systems have been protecting its customers for nearly 25 years against threats ranging from intercontinental ballistic missiles to hostile aircraft.The company has a long-term earnings growth rate of 19.3%. The Zacks Consensus Estimate for BAs 2025 sales indicates year-over-year growth of 22.1%.Lockheed Martin LMT: Lockheed Martins missile defense program includes the Patriot Advanced Capability-3 and Terminal High-Altitude Area Defense air and missile defense programs. It also manufactures the Multiple Launch Rocket System, the Joint Air-to-Surface Standoff Missile and Javelin tactical missile programs alongside other tactical missiles.The company has a long-term earnings growth rate of 4.4%. The Zacks Consensus Estimate for LMTs 2025 sales indicates year-over-year growth of 4.1%.

RTX shares have risen 15.2% in the past six months against the industrys 0.9% decline.

Image Source: Zacks Investment Research

RTX currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Lockheed Martin (LMT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this aerospace and defense company have returned -7%, compared to the Zacks S&P 500 composite's -2.7% change. During this period, the Zacks Aerospace - Defense industry, which Lockheed falls in, has lost 2.3%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Lockheed is expected to post earnings of $6.58 per share for the current quarter, representing a year-over-year change of -16.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.2%.

The consensus earnings estimate of $26.68 for the current fiscal year indicates a year-over-year change of -4.1%. This estimate has changed -0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $28.03 indicates a change of +5.1% from what Lockheed is expected to report a year ago. Over the past month, the estimate has changed -0.1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Lockheed.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Lockheed, the consensus sales estimate for the current quarter of $18.85 billion indicates a year-over-year change of -0.1%. For the current and next fiscal years, $71.27 billion and $74.17

billion estimates indicate +5.5% and +4.1% changes, respectively.

Lockheed reported revenues of $17.1 billion in the last reported quarter, representing a year-over-year change of +1.3%. EPS of $6.84 for the same period compares with $6.77 a year ago.

Compared to the Zacks Consensus Estimate of $17.28 billion, the reported revenues represent a surprise of -1.05%. The EPS surprise was +5.72%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Lockheed is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Lockheed. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Airbus SE EADSY secured a contract to provide logistics support and engineering services for the UH-72 Lakota helicopter. The award has been offered by the Army Contracting Command, Redstone Arsenal, AL.Valued at $315 million, the contract is expected to be completed by Dec. 31, 2025. The majority of the work related to this deal will be carried out in Grand Prairie, TX.

As nations are upgrading their defense capabilities, expenditures on cutting-edge defense equipment and ammunition have been rising quickly. Increasing expenditures on military helicopters, which are essential for air combat operations, contribute to the rising defense expenditures. As a leading manufacturer of combat helicopters, Airbus has received a steady stream of orders from all over the world.More than 140 armed forces worldwide rely on Airbus for its expertise to produce high-quality multi-role helicopters. These copters are able to fulfill a wide range of operational military roles, such as armed reconnaissance, utility, attack, naval, maritime and special operations.In particular, EADSYs UH-72 Lakota is a highly adaptable and reconfigurable helicopter capable of carrying out a wide range of tasks under a variety of climates and environments. Its missions are as diverse as its operational locations, encompassing training, general utility, search and rescue, reconnaissance, medical evacuation, disaster response, homeland security, counterdrug, command and control, and VIP transportation.

Amid rising military conflicts, terrorism and border disputes, these combat-proven helicopters play a critical role in a country's security system. This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 2.9% for the military helicopter market during the 2024-2030 period. Such growth opportunities offered by the aforementioned market should bode well for Airbus.EADSYs product portfolio consists of varied combat helicopters, such as the H125M, H160M, H175M, H215M, H225M, Tiger, NH90 and a few more. These enjoy solid demand in the global military helicopter market, with some 19,000 helicopters delivered across 150 nations.

Other defense companies that are expected to enjoy the perks of the expanding military helicopter market have been discussed below:Boeing BA: The companys helicopters are renowned for their leading-edge, relevant solutions that provide capacity. Boeings product portfolio includes combat helicopters and rotorcraft like the H-47 Chinook, AH-64 Apache, AH-6 Little Bird and V-22 Osprey.Boeing has a long-term (three to five years) earnings growth rate of 19.3%. The Zacks Consensus Estimate for BAs 2025 sales indicates an improvement of 21.9% from the 2024 estimated figure.Textron TXT: Its Bell business segment supplies advanced military helicopters and provides parts and support services to the U.S. Government and military customers outside the United States. Its portfolio of combat helicopters includes Bell 412M, Bell 429M, Bell 407M and Bell 505M. TXT boasts a long-term earnings growth rate of 10.1%. The Zacks Consensus Estimate for TXTs 2025 sales indicates year-over-year growth of 7.4% from the 2024 estimated figure.Lockheed Martin LMT: Its Sikorsky business unit provides military and rotary-wing aircraft to all five branches of the U.S. armed forces, along with military services and commercial operators in 40 nations. Some of LMTs renowned products are Armed Black Hawk, CH-53K, MH-60R SEAHAWK, Raider X, S-97 Raider, S-70 BLACK Hawk, etc.Lockheed boasts a long-term earnings growth rate of 4.4%. The Zacks Consensus Estimate for LMTs 2025 sales indicates an improvement of 3.9% from the 2024 estimated figure.

In the past six months, Airbus shares have risen 13.1% compared to the industrys fall of 1.7%.

Image Source: Zacks Investment Research

Airbus currently carries a Zacks Rank #4 (Sell).You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Airbus Group (EADSY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Sign in to access your portfolionstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Lockheed Martin Corporations LMT Aeronautics business segment recently clinched a modification contract to support the F-35 Joint Strike Fighter aircraft program. The award has been provided by the Naval Air Systems Command, Patuxent River, MD.

Valued at $678.4 million, the contract is expected to be completed by December 2028. Per the terms of the deal, Lockheed will provide various material modification kits, special test and tooling equipment, and associated seed assets to support the F-35 Joint Strike Fighter aircraft.The contract will serve the U.S. Navy, Air Force, Marine Corps and non-Department of Defense participants. The work related to this deal will be executed in Fort Worth, TX.

The F-35 program is widely recognized as the most advanced 5th-generation fighter jet, offering unmatched mission readiness. With cutting-edge sensors and communication systems, the F-35 is designed to operate seamlessly across multiple domains.These exceptional features must have been driving significant demand for the F-35 jets. This jet programs demand trend can be gauged from the fact that since its launch, Lockheed has delivered 1,040 units as of Sept. 29, 2024.

Rising military conflicts, terrorism and border disputes, along with rapid technological advancements in combat jets, have led nations to increase their defense spending on combat-proven jets, which constitute an integral part of their defense structure.This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 5.2% for the global military aviation market during the 2024-2030 period.Such strong market prospects drive growth opportunities for Lockheed Martin, backed by its robust portfolio of combat jets, including the F-16, F-22 and F-21 aircraft, in addition to the F-35 jet. Lockheed Martins total backlog was $165.69 billion as of Sept. 29, 2024.

Other defense companies that are likely to benefit from the expanding global fighter aircraft market are discussed below:Northrop Grumman Corporation NOC: Northrop provides manned and unmanned air systems. It builds some of the worlds most advanced aircraft like the E-2C Hawkeye 2000, A-10 Thunderbolt II, F-5 Tiger Fighter Jet and many more.Northrop has a long-term (three to five years) earnings growth rate of 19%. The Zacks Consensus Estimate for NOCs 2025 sales indicates year-over-year growth of 3.4%.Embraer ERJ: The company offers a comprehensive portfolio of the most advanced aircraft in the combat market, which includes the A-29 Super Tucano light attack and advanced trainer and the C-390 Millennium military multi-mission aircraft.The Zacks Consensus Estimate for ERJs 2025 sales indicates year-over-year growth of 18.3%. The company delivered an average earnings surprise of 127.28% in the last four quarters.The Boeing Company BA: Its Defense, Space & Security segment engages in the research, development, production and modification of manned and unmanned military aircraft. BAs product portfolio includes a range of combat-proven aircraft like the F/A-18 Super Hornet, P-8, C-17 Globemaster III, EA-18G and a few more.Boeing has a long-term earnings growth rate of 19.3%. The Zacks Consensus Estimate for BAs 2025 sales indicates year-over-year growth of 21.9%.

Shares of LMT have risen 2.9% in the past six months against the industrys 1% decline.

Image Source: Zacks Investment Research

LMT currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Zacks Investment Research

Sign in to access your portfolionstock news

The nations second largest airline is playing catch-up to rivals after its bet to overhaul corporate travel failed.

Sign in to access your portfolionstock news

Error fetching the URL: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4748423-lockheed-martin-recession-proof-your-portfolio-and-dividends-with-lmtnstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

(Reuters) - Lockheed Martin delivered a total of 110 F-35 fighter jets to the United States and its allies in 2024, the Bethesda, Maryland-based defense contractor said in a statement on Wednesday.

The delivery total achieves the higher end of the range of 75 to 110 jet deliveries CEO Jim Taiclet gave in an earnings call last summer.

Lockheed lifted its sales target in July after the Pentagon resumed taking F-35 deliveries following a months-long pause on delays on its software upgrade. Lockheed has been upgrading the jets under the Technology Refresh 3, or TR-3 program, which gives the F-35 better displays and processing power.

Lockheed's F-35 program contributes around 30% of the company's revenue.

"Lockheed Martin is fully committed to advancing and delivering unmatched air dominance solutions to the United States and our allies, helping to ensure America continues to own the skies," the company said in a statement.

(Reporting by Ryan Patrick Jones and Mike Stone; editing by Diane Craft)

Sign in to access your portfolio

Stock Detailsmeta:

version: v1.0

status: 200

copywrite: https://apicalls.io
symbol: Quotes Data
processedTime: 2025-01-12T05:04:33.296665Z
body:
- Item 1:
preMarketChange: None
preMarketChangePercent: None
preMarketPrice: None
preMarketTime: None
postMarketChange: None
postMarketChangePercent: None
postMarketPrice: None
postMarketTime: None
language: en-US
region: US
quoteType: NONE
triggerable: False
customPriceAlertConfidence: NONE
messageBoardId: finmb_91800
esgPopulated: False
corporateActions:
hasPrePostMarketData: False
tradeable: False
cryptoTradeable: False
symbol: AABA

Stock Detailsmeta:

version: v1.0

status: 200

copywrite: https://apicalls.io

symbol: Quotes Data

processedTime: 2025-01-12T05:04:35.023114Z

body:

- Item 1:

preMarketChange: None

preMarketChangePercent: None

preMarketPrice: None

preMarketTime: None

postMarketChange: -0.1

postMarketChangePercent: -0.579376

postMarketPrice: 17.16

postMarketTime: 1736550694

language: en-US

region: US

quoteType: EQUITY

typeDisp: Equity

quoteSourceName: Nasdaq Real Time Price

triggerable: True

customPriceAlertConfidence: HIGH

currency: USD

corporateActions:

regularMarketTime: 1736542802

exchange: NMS

messageBoardId: finmb_683713

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

esgPopulated: False

regularMarketChangePercent: -1.931819

regularMarketPrice: 17.26

shortName: ACADIA Pharmaceuticals Inc.

longName: ACADIA Pharmaceuticals Inc.

marketState: CLOSED

hasPrePostMarketData: True

firstTradeDateMilliseconds: 1085664600000

priceHint: 2

regularMarketChange: -0.34000015

regularMarketDayHigh: 17.715

regularMarketDayRange: 17.08 - 17.715

regularMarketDayLow: 17.08

regularMarketVolume: 2019460

regularMarketPreviousClose: 17.6

bid: 17.22

ask: 17.47

bidSize: 9

askSize: 23

fullExchangeName: NasdaqGS

financialCurrency: USD

regularMarketOpen: 17.23

averageDailyVolume3Month: 2303567

averageDailyVolume10Day: 6479600

fiftyTwoWeekLowChange: 3.1100006

fiftyTwoWeekLowChangePercent: 0.21978803

fiftyTwoWeekRange: 14.15 - 29.29

fiftyTwoWeekHighChange: -12.030001

fiftyTwoWeekHighChangePercent: -0.41072038

fiftyTwoWeekLow: 14.15

fiftyTwoWeekHigh: 29.29

fiftyTwoWeekChangePercent: -40.379967

earningsTimestamp: 1730927100

earningsTimestampStart: 1740481140

earningsTimestampEnd: 1741003200

earningsCallTimestampStart: 1730928600

earningsCallTimestampEnd: 1730928600

isEarningsDateEstimate: True

trailingAnnualDividendRate: 0

trailingPE: 22.128206

trailingAnnualDividendYield: 0

epsTrailingTwelveMonths: 0.78

epsForward: 0.82

epsCurrentYear: 0.69515

priceEpsCurrentYear: 24.829174

sharesOutstanding: 166392000

bookValue: 3.47

fiftyDayAverage: 16.8744

fiftyDayAverageChange: 0.38560104

fiftyDayAverageChangePercent: 0.022851245

twoHundredDayAverage: 16.39315

twoHundredDayAverageChange: 0.8668499

twoHundredDayAverageChangePercent: 0.052878786

marketCap: 2871926016

forwardPE: 21.04878

priceToBook: 4.9740634

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 2.1 - Buy

tradeable: False

cryptoTradeable: False

displayName: ACADIA Pharmaceuticals

symbol: ACAD

nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders should be happy to see the share price up 19% in the last quarter. But don't envy holders -- looking back over 5 years the returns have been really bad. Indeed, the share price is down 61% in the period. So we're not so sure if the recent bounce should be celebrated. However, in the best case scenario (far from fait accompli), this improved performance might be sustained.

If the past week is anything to go by, investor sentiment for ACADIA Pharmaceuticals isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

View our latest analysis for ACADIA Pharmaceuticals

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

During five years of share price growth, ACADIA Pharmaceuticals moved from a loss to profitability. That would generally be considered a positive, so we are surprised to see the share price is down. Other metrics may better explain the share price move.

Revenue is actually up 19% over the time period. So it seems one might have to take closer look at the fundamentals to understand why the share price languishes. After all, there may be an opportunity.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

ACADIA Pharmaceuticals is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

ACADIA Pharmaceuticals shareholders are down 43% for the year, but the market itself is up 26%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 10% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Is ACADIA Pharmaceuticals cheap compared to other companies? These 3 valuation measures might help you decide.

But note: ACADIA Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Sign in to access your portfolionstock news

Published: 2025-01-02 18:00:00 ET

ACAD

ACADIA Pharmaceuticals Inc.(NasdaqGS:ACAD) added to S&P 600 Health Care (Sector)nstock news

Published: 2025-01-02 18:00:00 ET

ACAD

ACADIA Pharmaceuticals Inc.(NasdaqGS:ACAD) added to S&P Composite 1500nstock news

Published: 2025-01-02 18:00:00 ET

ACAD

ACADIA Pharmaceuticals Inc.(NasdaqGS:ACAD) added to S&P 600nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other firms end 2024 stronger with impressive gains.

A lackluster trading persisted throughout the last day of the year, with Wall Streets main indices ending the day mixed.

The Dow Jones Industrial Average dipped by 0.07 percent, the S&P 500 shed 0.43 percent, and the

Nasdaq Composite declined by 0.90 percent. Meanwhile, NYSE Composite inched up by 0.10 percent and S&P Composite rose by 0.44 percent.

Despite the lack of catalysts to spark trading, 10 companiespredominantly in the biopharmaceuticals sectorposted impressive gains. Lets explore the reasons behind their outstanding performance.

To come up with Mondays top gainers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments.

Shares in ACADIA Pharmaceuticals (ACAD) increased by 9.95 percent on Wednesday, finishing the year higher at $18.35 apiece following news that it is set to join the S&P SmallCap 600 effective Friday, January 3, 2025, replacing Independent Bank Group Inc.

The S&P 600 is a stock market index tracking the performance of 600 small-cap companies in the US. It is designed to be a reliable benchmark for investors and traders and represents about 3 percent of the US market.

Year-to-date, however, registered a plunge of 40 percent from its valuation a year ago.

Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company specializing in innovative treatments for central nervous system (CNS) disorders including Parkinsons disease psychosis, Alzheimer s-related psychosis, schizophrenia, and Rett syndrome.

It owns NUPLAZID, an FDA-approved treatment for Parkinsons psychosis. Acadias robust research and development pipeline focuses on the growing needs in neurology and psychiatry.

Overall, ACAD ranks 1st on our list of firms end 2024 stronger with impressive gains. While we acknowledge the potential of ACAD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ACAD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.

Sign in to access your portfolionstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE: SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

Following is a summary of the change that will take place prior to the open of trading on the effective date:

Effective Date

Index Name

Action

Company Name

Ticker

GICS Sector

Jan 3, 2025

S&P SmallCap 600

Addition

Acadia Pharmaceuticals

ACAD

Health Care

Jan 3, 2025

S&P SmallCap 600

Deletion

Independent Bank Group

IBTX

Financials

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

S&P Dow Jones Indicesindex_services@spglobal.com

Media Inquiriesspdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

SOURCE S&P Dow Jones Indices

SAN DIEGO, December 19, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the Company in a session scheduled on Tuesday, January 14, 2025, at 9:00 a.m. Pacific Time / 12:00 p.m.

Eastern Time.

A live webcast of Acadias presentation will be accessible on the companys website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinsons disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimers disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241219997230/en/

Contacts

Investor Contact: Acadia Pharmaceuticals Inc.Al Kildani(858) 261-2872ir@acadia-pharm.com

Published: 2024-12-17 10:00:52 ET

ACAD

SAN DIEGO - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadia's Board of Directors (the 'Committee') granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units ('RSUs') to thirteen new employees under Acadia's 2024 Inducement Plan.

The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(4).

Each stock option has an exercise price per share equal to $17.17 per share, Acadia's closing trading price on December 4, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees' continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadia's 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson's disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer's disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders.

Contact:

Al Kildani

Tel: (858) 261-2872

Email:

SAN DIEGO, December 16, 2024--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on December 4, 2024, the Compensation Committee of Acadias Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 38,568 shares of common stock and 22,264 restricted stock units ("RSUs") to thirteen new employees under Acadias 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $17.17 per share, Acadias closing trading price on December 4, 2024, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees continued service relationship with Acadia through the applicable vesting dates. The RSUs will vest over four years, with 50% of the underlying shares vesting on the second anniversary of the grant date, and the balance of the underlying shares vesting in two equal annual installments measured from the second anniversary of the grant date, subject to the new employees continued service relationship with Acadia through the applicable vesting dates. The awards are subject to the terms and conditions of Acadias 2024 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinsons disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimers disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241216033013/en/

Contacts

Investor Contact: Acadia Pharmaceuticals Inc.Al Kildani(858) 261-2872ir@acadia-pharm.com

The United States market has remained flat over the last week but is up 29% over the past year, with earnings expected to grow by 15% per annum. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for revenue expansion and innovation while aligning with broader market trends.

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.83%

24.32%

Ardelyx

25.47%

69.63%

Sarepta Therapeutics

23.98%

42.48%

Alnylam Pharmaceuticals

22.38%

70.33%

Clene

77.61%

59.19%

TG Therapeutics

34.66%

56.98%

Alkami Technology

21.94%

98.60%

Travere Therapeutics

31.70%

72.51%

Seagen

22.57%

71.80%

ImmunoGen

26.00%

45.85%

Click here to see the full list of 242 stocks from our US High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Simply Wall St Growth Rating:

Overview: Capricor Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy and other diseases with unmet medical needs, with a market cap of $676.14 million.

Operations: Capricor Therapeutics focuses on developing cell and exosome-based therapeutics, primarily targeting Duchenne muscular dystrophy. The company generates revenue from its biotechnology segment, amounting to $23.23 million.

Capricor Therapeutics, despite its current unprofitability, is poised for significant growth with projected revenue increases of 53.2% annually, outpacing the broader US market's 9.1% growth rate. This biotech firm is navigating a transformative phase, evidenced by its strategic shift towards high-potential treatments like deramiocel for Duchenne muscular dystrophy (DMD) cardiomyopathy. Recent R&D investments have catalyzed promising clinical outcomes, positioning Capricor at the forefront of DMD treatment innovation. Moreover, the company's recent equity offerings and partnerships underscore a robust financial strategy to support its ambitious R&D endeavors and potential market expansion in Europe with Nippon Shinyaku Co., Ltd., enhancing its commercial footprint and future revenue streams.

Click here and access our complete health analysis report to understand the dynamics of Capricor Therapeutics.

Assess Capricor Therapeutics' past performance with our detailed historical performance reports.

Simply Wall St Growth Rating:

Overview: ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative medicines for central nervous system disorders and rare diseases in the United States, with a market cap of approximately $3.08 billion.

Operations: ACADIA Pharmaceuticals focuses on developing and commercializing medicines for central nervous system disorders and rare diseases, generating approximately $929.24 million in revenue from these activities.

ACADIA Pharmaceuticals has recently turned a corner, posting a net income of $32.77 million in Q3 2024, contrasting sharply with the previous year's loss of $65.18 million. This transformation is underscored by robust R&D investments, which have fueled significant clinical advancements and contributed to an impressive expected earnings growth rate of 26.6% per year. The company's strategic executive reshuffling, including the appointment of Thomas Andrew Garner as Chief Commercial Officer, aims to further capitalize on these advances by expanding its commercial footprint both domestically and internationally. With R&D expenses aligning closely with revenue increasesevidenced by a substantial rise from last years figuresthe firm is strategically positioning itself for sustained growth in the competitive biotech landscape.

Take a closer look at ACADIA Pharmaceuticals' potential here in our health report.

Evaluate ACADIA Pharmaceuticals' historical performance by accessing our past performance report.

Simply Wall St Growth Rating:

Overview: Ubiquiti Inc. develops networking technology for service providers, enterprises, and consumers and has a market capitalization of $20.13 billion.

Operations: Ubiquiti generates revenue primarily from its Wireless Communications Equipment segment, amounting to approximately $2.02 billion. The company focuses on providing networking technology solutions across various sectors including service providers and enterprises.

Ubiquiti's recent performance showcases robust growth with a notable increase in sales to $550.34 million and net income rising to $127.99 million, up from $87.75 million last year, reflecting a solid earnings per share increase from $1.45 to $2.12. This financial uplift is mirrored in the company's strategic R&D investments, which are essential for maintaining its competitive edge in the tech sector; these efforts are expected to fuel revenue and earnings growth by 12.5% and 29% per year respectively, outpacing the US market averages of 9.1% and 15.4%. Despite being dropped from the FTSE All-World Index, Ubiquiti continues to attract attention with its forward-looking initiatives, including a recent dividend declaration which underscores its commitment to shareholder returns amidst expanding operations.

Get an in-depth perspective on Ubiquiti's performance by reading our health report here.

Gain insights into Ubiquiti's past trends and performance with our Past report.

Gain an insight into the universe of 242 US High Growth Tech and AI Stocks by clicking here.

Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

Find companies with promising cash flow potential yet trading below their fair value.

Companies discussed in this article include NasdaqCM:CAPR NasdaqGS:ACAD and NYSE:UI.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Regarding retirement savings, we all hear about the elusive "top 3%." But how much does it take to get there? Turns out, the number might surprise you. According to data from the Federal Reserve and the Employee Benefit Research Institute, just 3.2% of retirees have saved over $1 million. That's not chump change, but it's also not the $5-$10 million range some financial gurus like Suze

Orman insist you must live comfortably. If you're dreaming of $3 million or more, though, you're officially

The Nasdaq Composite is up 33.5% this year, while the Ark Innovation ETF has returned 18.03%.

A trio of quantum-computing stocks have seen huge gains over the past few months, bolstered by a wave of hype from retail investors looking to cash in on what could be the next big thing in tech.

Shares of Palantir Technologies (NASDAQ: PLTR) have more than quadrupled year to date over unrelenting demand for the company's new artificial intelligence platform. In that context, Shopify (NYSE: SHOP) and Arm Holdings (NASDAQ: ARM) present more compelling investment options. Palantir is currently worth $165 billion, but I think Shopify and Arm can top that figure before the end of 2025.

Investors looking for value stocks to buy before the new year have come to the right place.

This has been an excellent year for the broader index as well as the industrial sector, with all-time highs across machinery companies and defense contractors. A big reason for a further sell-off could be fears of lower interest rates for longer. The U.S. small-package delivery market has excess capacity due to lower-than-expected delivery volumes in recent years.

Building long-term wealth isn't necessarily easy, but investing in the stock market is one of the simplest ways to do it. While there's not necessarily a right or wrong place to invest, this Vanguard ETF could potentially double your money over time with next to no effort on your part. The Vanguard S&P 500 Growth ETF (NYSEMKT: VOOG) is essentially a hybrid between an S&P 500 ETF and a growth ETF, as it contains only the growth companies within the S&P 500 index (SNPINDEX: ^GSPC).

Cleveland-Cliffs (CLF) closed at $12.22 in the latest trading session, marking a -0.49% move from the prior day.

This particular moment happened a few weeks ago when institutional investors managing at least $100 million filed their 13F forms with the Securities and Exchange Commission (SEC). In the most recent quarter, billionaire Ole Andreas Halvorsen took a big step in the hot area of artificial intelligence (AI), selling all of his Broadcom (NASDAQ: AVGO) shares and piling into this year's top

Dow Jones Industrial average performer. At the helm of Viking Global Investors, Halvorsen helps manage more than $27 billion in securities falling under 13F reporting requirements.

Adobe stock fell after the creative software giant provided a weaker-than-expected outlook for the 2025 fiscal year.

Sign in to access your portfolio

Stock Detailsmeta:
  version: v1.0
  status: 200
  copywrite: https://apicalls.io
  symbol: Quotes Data
  processedTime: 2025-01-12T05:05:07.876445Z
body:

Stock Detailsmeta:
  version: v1.0
  status: 200
  copywrite: https://apicalls.io
  symbol: Quotes Data
  processedTime: 2025-01-12T05:05:11.058723Z
body:
  - Item 1:
    preMarketChange: None
    preMarketChangePercent: None
    preMarketPrice: None
    preMarketTime: None
    postMarketChange: -2.19
    postMarketChangePercent: -1.59308

postMarketPrice: 135.28

postMarketTime: 1736557181

language: en-US

region: US

quoteType: EQUITY

typeDisp: Equity

quoteSourceName: Nasdaq Real Time Price

triggerable: True

customPriceAlertConfidence: HIGH

currency: USD

exchange: NYQ

messageBoardId: finmb_154924

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

esgPopulated: False

regularMarketChangePercent: 0.343067

regularMarketPrice: 137.47

shortName: Agilent Technologies, Inc.

longName: Agilent Technologies, Inc.

marketState: CLOSED

corporateActions:

regularMarketTime: 1736542802

hasPrePostMarketData: True

firstTradeDateMilliseconds: 942935400000

priceHint: 2

fullExchangeName: NYSE

financialCurrency: USD

regularMarketOpen: 134.75

averageDailyVolume3Month: 1726772

averageDailyVolume10Day: 1026030

fiftyTwoWeekLowChange: 13.309998

fiftyTwoWeekLowChangePercent: 0.10720036

fiftyTwoWeekRange: 124.16 - 155.35

fiftyTwoWeekHighChange: -17.880005

fiftyTwoWeekHighChangePercent: -0.115094975

fiftyTwoWeekLow: 124.16

fiftyTwoWeekHigh: 155.35

fiftyTwoWeekChangePercent: 5.316782

dividendDate: 1737504000

earningsTimestamp: 1732568400

earningsTimestampStart: 1740481140

earningsTimestampEnd: 1741003200

earningsCallTimestampStart: 1732570200

earningsCallTimestampEnd: 1732570200

isEarningsDateEstimate: True

trailingAnnualDividendRate: 0

trailingPE: 31.031605

trailingAnnualDividendYield: 0

epsTrailingTwelveMonths: 4.43

epsForward: 5.65

epsCurrentYear: 5.56626

priceEpsCurrentYear: 24.697014

sharesOutstanding: 285595008

bookValue: 20.53

fiftyDayAverage: 135.6568

fiftyDayAverageChange: 1.8132019

fiftyDayAverageChangePercent: 0.013366097

twoHundredDayAverage: 137.9748

twoHundredDayAverageChange: -0.50479126

twoHundredDayAverageChangePercent: -0.003658576

marketCap: 39260745728

forwardPE: 24.330973

priceToBook: 6.6960545

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 2.3 - Buy

tradeable: False

cryptoTradeable: False

regularMarketChange: 0.470001

regularMarketDayHigh: 140

regularMarketDayRange: 134.709 - 140.0

regularMarketDayLow: 134.709

regularMarketVolume: 1069430

regularMarketPreviousClose: 137

bid: 129.75

ask: 142.1

bidSize: 8

askSize: 9

displayName: Agilent

symbol: A

nstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-falls-wednesday-underperforms-market-94c90b4a-ecf4b3eed4eanstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-rises-tuesday-outperforms-market-047616db-2a6051ccb659nstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-rises-monday-still-underperforms-market-7371264d-0f74721e0577nstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-falls-thursday-underperforms-market-741ce254-ca531cba2e97nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Impax Asset Management, an investment management company, released its Impax Global Environmental Markets Fund third quarter 2024 investor letter. A copy of the letter can be downloaded here. The MSCI All Country World Index (MSCI ACWI), which measures global equities, saw gains throughout the quarter as monetary easing by the US and Chinese central banks gave markets additional momentum and offset political and geopolitical unpredictability. A new cycle of rate-cutting in the US started in the last weeks of the quarter, catalysed by improving job and inflation data. The strategy appreciated and outperformed its primary benchmark, the MSCI ACWI during the quarter. The portfolio benefited from a reversal in mega-cap outperformance and improved market breadth in third quarter, following an extended period of extreme market narrowness. In addition, you can check the funds top 5 holdings to determine its best picks for 2024.

Impax Global Environmental Markets Fund highlighted stocks like Agilent Technologies, Inc.

(NYSE:A) in its Q3 2024 investor letter. Agilent Technologies, Inc. (NYSE:A) offers application-focused solutions to life sciences, diagnostics, and applied chemical markets. The one-month return of Agilent Technologies, Inc. (NYSE:A) was -4.18%, and its shares gained 2.42% of their value over the last 52 weeks. On December 31, 2024, Agilent Technologies, Inc. (NYSE:A) stock closed at $134.34 per share with a market capitalization of $38.367 billion.

Impax Global Environmental Markets Fund stated the following regarding Agilent Technologies, Inc. (NYSE:A) in its Q3 2024 investor letter:

"Agilent Technologies, Inc. (NYSE:A) (Environmental Testing & Monitoring, US) rebounded during the quarter driven by an encouraging earnings release, indicating improving end-market conditions. Q3 top- and bottom-line results exceeded expectations, driven by strength in their instruments business. Guidance was modestly raised, and the companys book-to-bill ratio was greater than 1 for the second consecutive quarter."

A medical professional demonstrating the use of a Software-Based Prescription Digital Therapeutics Platform for treating Type 2 Diabetes.

Agilent Technologies, Inc. (NYSE:A) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 44 hedge fund portfolios held Agilent Technologies, Inc. (NYSE:A) at the end of the third quarter which was 40 in the previous quarter. Agilent Technologies, Inc.'s (NYSE:A) revenue was $1.701 billion in the third quarter, a decline of 0.3% core from previous year's quarter. While we acknowledge the potential of Agilent Technologies, Inc. (NYSE:A) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we discussed Agilent Technologies, Inc. (NYSE:A) and shared the list of stocks on Jim Cramers radar. In addition, please check out our hedge fund investor letters Q3 2024 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.

Sign in to access your portfolionstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

We recently compiled a list of the 8 Stocks on Jim Cramer's Radar. In this article, we are going to take a look at where Agilent Technologies, Inc. (NYSE:A) stands against the other stocks.

Jim Cramer, the host of Mad Money, recently shared some investment guidelines based on his 40 years of experience. As we previously discussed in our article, Jim Cramer Talked About These 8 Stocks, Cramer emphasized that both bulls and bears can profit, but greed leads to losses, advising investors to take profits and avoid being overly greedy. His second rule is that paying taxes is acceptable. Finally, Cramer stressed the importance of not making large, all-at-once buys or sales, recommending gradual adjustments to positions instead.

In addition to these guidelines, Cramers next rule was to recognize the importance of distinguishing between damaged stocks and damaged companies. He explained that buying stocks from companies that are fundamentally flawed is a mistake with no chance of recovery, but stocks of companies that are simply experiencing temporary issues may present a buying opportunity. This distinction is critical because, as Cramer pointed out, theres no money-back guarantee when buying into a company with long-term problems.

Investors should focus on finding stocks that are down for reasons that arent related to poor company fundamentals. Cramer then moved on to his next rule, which is to always do the relevant homework.

If you want to build a portfolio of individual stocks, that's a big if since there's nothing wrong with getting all of your equity exposure from a cheap index fund that mirrors the S&P 500, well, you gotta be rigorous about it. Which brings me to my next rule: Do the homework.

READ ALSO Jim Cramers Latest Lightning Round: 8 Stocks in Focus and Jim Cramer Discussed These 11 Restaurants and Retail Stocks

Cramer said that doing the homework means more than just picking stocks based on a gut feeling; it involves actively researching companies by listening to earnings calls, reading research reports, and staying on top of the news. Cramer noted that some investors dismiss this kind of work, seeing it as unnecessary or outdated in todays fast-paced world. However, he was clear in his belief that failing to do proper research before buying stocks is foolish and can lead to poor investment choices.

Cramer further emphasized that doing homework today is easier than ever. With so much information available on the internet, there's no excuse for not gathering as much data as possible. For those who dont have the time or inclination to dive deep into individual stocks, Cramer suggested that index funds are a great alternative. Another crucial rule that Cramer continually stresses is the importance of diversification.

The next rule is another essential that I harp on constantly: Diversify, diversify, and diversify. Always be diversified, that controls risk, and managing risk is really the holy grail of this business. What's the biggest risk out there? It's called sector risk.

Sector risk refers to the potential for a specific sector of the economy to lag, which can result in negative impacts on investments within that sector. Cramer explained that sector risk is one of the most significant dangers to an investment portfolio, and diversification is the only way to protect against it.

He frequently says that "diversification is the only free lunch in this business" because its the one investment principle that benefits everyone. As per Cramer, by mixing different sectors in a portfolio, at least five according to him, investors can prevent themselves from suffering catastrophic losses if one particular sector takes a hit.

Here's the bottom line: Whether you're an amateur or professional, you always need to do your homework and keep your portfolio diversified. This is the kind of routine maintenance that protects you from monster losses down the line. Remember, if you can keep your losses to a minimum and let your gains run, you almost always come out ahead. But don't try to rationalize those losses because stocks don't always come back to even or anywhere near that.

Our Methodology

For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the episodes of Mad Money. We listed the stocks in ascending order of their hedge fund sentiment as of the third quarter, which was taken from Insider Monkeys database of 900 hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletters strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

An expert investment advisor consulting a high net worth individual in a modern office.

Number of Hedge Fund Holders: 44

Discussing Agilent Technologies, Inc. (NYSE:A), Cramer said:

Finally, how about Agilent Technologies, letter A, a company that provides instruments, software, and services for customers in the life sciences, diagnostics, and applied industrial end markets? This one's down more than 14% from its 52-week high in May. Agilents in the news because the company hosted an analyst day yesterday and from what I hear, they told a pretty good story.

At its recent analyst day, the company reaffirmed its long-term revenue growth forecast of 5-7%, exceeding market expectations, and slightly raised its operating margin expansion targets (50-100+ bps/yr), indicating potential growth fueled by revenue leverage and strategic initiatives such as Ignite.

The company's Ignite plan focuses on driving growth through innovation, simplifying processes with a customer-first approach, and improving operational productivity. Furthermore, Cramer also highlighted the companys recent reorganization. Acknowledging that the analyst day did not lead to much stock activity, Cramer said:

Now, the analyst day didn't have much impact on the stock, but I think it was a good reintroduction for this fine company which might have fallen off investors radar during this listless period for the life science space.

In November, the company announced the new organizational structure to improve collaboration and better align with customer needs. The three business groups include Life Sciences and

Diagnostics Markets Group (LDG), representing 38% of revenue, which focuses on pharma, biopharma, clinical, and diagnostics markets.

The Applied Markets Group (AMG), accounting for 20% of revenue, serves industries such as food, environmental, forensics, and chemicals. The Agilent CrossLab Group (ACG), making up 42% of revenue, supports all end markets by strengthening customer connections and providing services, software, and consumables.

Overall A ranks 3rd on our list of stocks on Jim Cramer's radar. While we acknowledge the potential of A as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than A but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.

Sign in to access your portfolionstock news

Error fetching the URL: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4746771-dividend-champion-contender-and-challenger-highlights-week-of-december-29nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

A month has gone by since the last earnings report for Agilent Technologies (A). Shares have added about 1.3% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Agilent Technologies reported fourth-quarter fiscal 2024 earnings of $1.46 per share, which beat the Zacks Consensus Estimate by 3.6%. The figure increased 5.8% year over year.Revenues of $1.70 billion surpassed the Zacks Consensus Estimate by 1.67%. The top line increased 0.8% on a reported basis and moved down 0.3% on a core basis from the year-ago quarter.This growth was driven by advancements in the Pharmaceutical, Diagnostics and Clinical sectors, along with improvements in the Chemical and Advanced Materials markets.However, the company faced challenges in the Food, Academic and Government, and Environmental and Forensics markets in the reported quarter.Modest weakening conditions in the Americas and China region were significant headwinds, whereas growing momentum across Europe and the Asia Pacific provided a tailwind.

Agilent currently has three reporting segments Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).LSAG: The segment generated $833 million or 49% of the companys total revenues. This marked a 1% decline both on a reported and core basis compared with the prior-year quarter. This was due to softness in the instrument business as customers took a cautious approach toward capital expenditures. However, this was offset by strong demand for analytical lab consumables, which demonstrated mid-single-digit growth or better across all end markets and regions.ACG: Revenues from the segment were $426 million, accounting for 25% of the total revenues. The top line grew 5% on a reported basis and 5% on a core basis compared with the prior-year quarter. This was driven by strong growth in contract business, including the fast-expanding Enterprise Services segment, which posted double-digit growth in the reported quarter. ACG achieved growth in all markets and regions except China, which was flat year over year but improved sequentially.DGG: Revenues decreased 1% year over year on a reported and 3% on a core basis to $442 million, accounting for the remaining 26% of the total revenues. This was led by expected softness in Cell Analysis and NASD, partially offset by strong high-single-digit growth in the Cancer Dx business and improved results in Genomics.The company recently unveiled a new organizational structure, aimed at accelerating its operational transformation and driving higher growth through a market-focused, customer-centric strategy. The new structure includes the Life Sciences and Diagnostics Markets Group (LDG), Applied Markets Group (AMG) and Agilent Cross Lab Group (ACG).

For the fourth quarter of 2024, the gross margin in the LSAG segment contracted 40 basis points (bps) to 59.1% from the prior-year quarter. ACGs gross margin expanded 50 bps to 50.9%. DGGs gross margin contracted 220 bps year over year to 51.5%.Research and development (R&D) expenses on a non-GAAP basis were $109 million, down 6% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose slightly to $362 million, marking a 1.4% increase from the prior-year quarter.As a percentage of revenues, R&D expenses fell 50 bps year over year to 6.4%, whereas SG&A expenses grew 10 bps year over year to 21.3%.The non-GAAP operating margin of 27.4% for the fiscal fourth quarter of 2024 indicates a year-over-year contraction of 40 bps.Segment-wise, the operating margin in the LSAG segment declined 60 bps to 28% from the prior-year quarter. ACGs operating margin fell 180 bps year over year to 32.6%. Meanwhile, the DGGs operating margin contracted 140 bps year over year to 21.3%.

As of Oct. 31, 2024, Agilents cash and cash equivalents were $1.33 billion, down from $1.78 billion as of July 31, 2024.Accounts receivables were $1.32 billion at the end of the fourth quarter of fiscal 2024 compared with $1.23 billion at the end of the third quarter.The long-term debt was $3.35 billion for the reported quarter compared with $2.14 billion in the prior quarter.Cash flow from operating activities was $481 million in the fourth quarter of fiscal 2024 compared with $452 million in the previous quarter.

For the first quarter of fiscal 2025, management expects revenues of $1.650-$1.680 billion, indicating a decline of 0.5% against an increase of 1.3% on a reported basis and a decrease of 2% versus a rise of 0.2% on a core basis from the year-ago quarters actuals.Non-GAAP fiscal first-quarter earnings per share are expected to be $1.25-$1.28.For fiscal 2025, management revised its revenue guidance from $6.45-$6.50 billion to $6.79-$6.87 billion, implying an increase of 4.3-5.5% on a reported basis and 2.5-3.5% on a core basis from the fiscal 2024 reported figure.The company also revised fiscal 2025 non-GAAP earnings per share guidance from $5.21-$5.25 to $5.54-$5.61.

It turns out, estimates revision have trended downward during the past month.

The consensus estimate has shifted -8.21% due to these changes.

Currently, Agilent has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Agilent has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

Investors in Agilent Technologies, Inc. A need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $80.00 Call had some of the highest implied volatility of all equity options today.

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

Clearly, options traders are pricing in a big move for Agilent shares, but what is the fundamental picture for the company? Currently, Agilent is a Zacks Rank #4 (Sell) in the Electronics - Testing Equipment industry that ranks in the Bottom 34% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while four have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from earnings of $1.38 per share to $1.27 in that period.Given the way analysts feel about Agilent right now, this huge implied volatility could mean theres a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Zacks Investment Research

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-rises-friday-still-underperforms-market-2fbe1176-235eafd36509

Stock Detailsmeta:

version: v1.0

status: 200

copywrite: https://apicalls.io

symbol: Quotes Data

processedTime: 2025-01-12T05:05:35.411517Z body:

- Item 1:

preMarketChange: None

preMarketChangePercent: None

preMarketPrice: None

preMarketTime: None

postMarketChange: -2.19

postMarketChangePercent: -1.59308

postMarketPrice: 135.28

postMarketTime: 1736557181

language: en-US

region: US

quoteType: EQUITY

typeDisp: Equity

quoteSourceName: Nasdaq Real Time Price

triggerable: True

customPriceAlertConfidence: HIGH

currency: USD

corporateActions:

regularMarketTime: 1736542802

exchange: NYQ

messageBoardId: finmb_154924

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

esgPopulated: False

firstTradeDateMilliseconds: 942935400000

priceHint: 2

regularMarketChange: 0.470001

regularMarketDayHigh: 140

regularMarketDayRange: 134.709 - 140.0

regularMarketDayLow: 134.709

regularMarketVolume: 1069430

regularMarketPreviousClose: 137

bid: 129.75

ask: 142.1

bidSize: 8

askSize: 9

fullExchangeName: NYSE

financialCurrency: USD

regularMarketOpen: 134.75

averageDailyVolume3Month: 1726772

averageDailyVolume10Day: 1026030

fiftyTwoWeekLowChange: 13.309998

fiftyTwoWeekLowChangePercent: 0.10720036

fiftyTwoWeekRange: 124.16 - 155.35

fiftyTwoWeekHighChange: -17.880005

fiftyTwoWeekHighChangePercent: -0.115094975

fiftyTwoWeekLow: 124.16

fiftyTwoWeekHigh: 155.35

fiftyTwoWeekChangePercent: 5.316782

dividendDate: 1737504000

earningsTimestamp: 1732568400

earningsTimestampStart: 1740481140

earningsTimestampEnd: 1741003200

earningsCallTimestampStart: 1732570200

earningsCallTimestampEnd: 1732570200

isEarningsDateEstimate: True

trailingAnnualDividendRate: 0

trailingPE: 31.031605

trailingAnnualDividendYield: 0

epsTrailingTwelveMonths: 4.43

epsForward: 5.65

epsCurrentYear: 5.56626

priceEpsCurrentYear: 24.697014

sharesOutstanding: 285595008

bookValue: 20.53

fiftyDayAverage: 135.6568

fiftyDayAverageChange: 1.8132019

fiftyDayAverageChangePercent: 0.013366097

twoHundredDayAverage: 137.9748

twoHundredDayAverageChange: -0.50479126

twoHundredDayAverageChangePercent: -0.003658576

marketCap: 39260745728

forwardPE: 24.330973

priceToBook: 6.6960545

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 2.3 - Buy

marketState: CLOSED

regularMarketChangePercent: 0.343067

regularMarketPrice: 137.47

longName: Agilent Technologies, Inc.

tradeable: False

cryptoTradeable: False

shortName: Agilent Technologies, Inc.

hasPrePostMarketData: True

displayName: Agilent

symbol: A

nstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-falls-wednesday-underperforms-market-94c90b4a-ecf4b3eed4eanstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-rises-tuesday-outperforms-market-047616db-2a6051ccb659nstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-rises-monday-still-underperforms-market-7371264d-0f74721e0577nstock news

Error fetching the URL: 401 Client Error: HTTP Forbidden for url: https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-falls-thursday-underperforms-market-741ce254-ca531cba2e97nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Impax Asset Management, an investment management company, released its Impax Global Environmental Markets Fund third quarter 2024 investor letter. A copy of the letter can be downloaded here. The MSCI All Country World Index (MSCI ACWI), which measures global equities, saw gains throughout the quarter as monetary easing by the US and Chinese central banks gave markets additional momentum and offset political and geopolitical unpredictability. A new cycle of rate-cutting in the US started in the last weeks of the quarter, catalysed by improving job and inflation data. The strategy appreciated and outperformed its primary benchmark, the MSCI ACWI during the quarter. The portfolio benefited from a reversal in mega-cap outperformance and improved market breadth in third quarter, following an extended period of extreme market narrowness. In addition, you can check the funds top 5 holdings to determine its best picks for 2024.

Impax Global Environmental Markets Fund highlighted stocks like Agilent Technologies, Inc. (NYSE:A) in its Q3 2024 investor letter. Agilent Technologies, Inc. (NYSE:A) offers application-focused solutions to life sciences, diagnostics, and applied chemical markets. The one-month return of Agilent Technologies, Inc. (NYSE:A) was -4.18%, and its shares gained 2.42% of their value over the last 52 weeks. On December 31, 2024, Agilent Technologies, Inc. (NYSE:A) stock closed at $134.34 per share with a market capitalization of $38.367 billion.

Impax Global Environmental Markets Fund stated the following regarding Agilent Technologies, Inc. (NYSE:A) in its Q3 2024 investor letter:

"Agilent Technologies, Inc. (NYSE:A) (Environmental Testing & Monitoring, US) rebounded during the quarter driven by an encouraging earnings release, indicating improving end-market conditions. Q3 top- and bottom-line results exceeded expectations, driven by strength in their instruments business. Guidance was modestly raised, and the companys book-to-bill ratio was greater than 1 for the second consecutive quarter."

A medical professional demonstrating the use of a Software-Based Prescription Digital Therapeutics Platform for treating Type 2 Diabetes.

Agilent Technologies, Inc. (NYSE:A) is not on our list of 31 Most Popular Stocks Among Hedge Funds. As per our database, 44 hedge fund portfolios held Agilent Technologies, Inc. (NYSE:A) at the end of the third quarter which was 40 in the previous quarter. Agilent Technologies, Inc.'s (NYSE:A) revenue was $1.701 billion in the third quarter, a decline of 0.3% core from previous year's quarter. While we acknowledge the potential of Agilent Technologies, Inc. (NYSE:A) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

In another article, we discussed Agilent Technologies, Inc. (NYSE:A) and shared the list of stocks on Jim Cramers radar. In addition, please check out our hedge fund investor letters Q3 2024 page for more investor letters from hedge funds and other leading investors.

READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.

Disclosure: None. This article is originally published at Insider Monkey.

We recently compiled a list of the 8 Stocks on Jim Cramer's Radar. In this article, we are going to take a look at where Agilent Technologies, Inc. (NYSE:A) stands against the other stocks.

Jim Cramer, the host of Mad Money, recently shared some investment guidelines based on his 40 years of experience. As we previously discussed in our article, Jim Cramer Talked About These 8 Stocks, Cramer emphasized that both bulls and bears can profit, but greed leads to losses, advising investors to take profits and avoid being overly greedy. His second rule is that paying taxes is acceptable. Finally, Cramer stressed the importance of not making large, all-at-once buys or sales, recommending gradual adjustments to positions instead.

In addition to these guidelines, Cramers next rule was to recognize the importance of distinguishing between damaged stocks and damaged companies. He explained that buying stocks from companies that are fundamentally flawed is a mistake with no chance of recovery, but stocks of companies that are simply experiencing temporary issues may present a buying opportunity. This distinction is critical because, as Cramer pointed out, theres no money-back guarantee when buying into a company with long-term problems.

Investors should focus on finding stocks that are down for reasons that arent related to poor company fundamentals. Cramer then moved on to his next rule, which is to always do the relevant homework.

If you want to build a portfolio of individual stocks, that's a big if since there's nothing wrong with getting all of your equity exposure from a cheap index fund that mirrors the S&P 500, well, you gotta be rigorous about it. Which brings me to my next rule: Do the homework.

READ ALSO Jim Cramers Latest Lightning Round: 8 Stocks in Focus and Jim Cramer Discussed These 11 Restaurants and Retail Stocks

Cramer said that doing the homework means more than just picking stocks based on a gut feeling; it involves actively researching companies by listening to earnings calls, reading research reports, and staying on top of the news. Cramer noted that some investors dismiss this kind of work, seeing it as unnecessary or outdated in todays fast-paced world. However, he was clear in his belief that failing to do proper research before buying stocks is foolish and can lead to poor investment choices.

Cramer further emphasized that doing homework today is easier than ever. With so much information available on the internet, there's no excuse for not gathering as much data as possible. For those who dont have the time or inclination to dive deep into individual stocks, Cramer suggested that index funds are a great alternative. Another crucial rule that Cramer continually stresses is the importance of diversification.

The next rule is another essential that I harp on constantly: Diversify, diversify, and diversify. Always be diversified, that controls risk, and managing risk is really the holy grail of this business. What's the biggest risk out there? It's called sector risk.

Sector risk refers to the potential for a specific sector of the economy to lag, which can result in negative impacts on investments within that sector. Cramer explained that sector risk is one of the most significant dangers to an investment portfolio, and diversification is the only way to protect against it.

He frequently says that "diversification is the only free lunch in this business" because its the one investment principle that benefits everyone. As per Cramer, by mixing different sectors in a portfolio, at least five according to him, investors can prevent themselves from suffering catastrophic losses if one particular sector takes a hit.

Here's the bottom line: Whether you're an amateur or professional, you always need to do your homework and keep your portfolio diversified. This is the kind of routine maintenance that protects you from monster losses down the line. Remember, if you can keep your losses to a minimum and let your gains run, you almost always come out ahead. But don't try to rationalize those losses because stocks don't always come back to even or anywhere near that.

Our Methodology

For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the episodes of Mad Money. We listed the stocks in ascending order of their hedge fund sentiment as of the third quarter, which was taken from Insider Monkeys database of 900 hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletters strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

An expert investment advisor consulting a high net worth individual in a modern office.

Number of Hedge Fund Holders: 44

Discussing Agilent Technologies, Inc. (NYSE:A), Cramer said:

Finally, how about Agilent Technologies, letter A, a company that provides instruments, software, and services for customers in the life sciences, diagnostics, and applied industrial end markets? This one's down more than 14% from its 52-week high in May. Agilents in the news because the company hosted an analyst day yesterday and from what I hear, they told a pretty good story.

At its recent analyst day, the company reaffirmed its long-term revenue growth forecast of 5-7%, exceeding market expectations, and slightly raised its operating margin expansion targets (50-100+ bps/yr), indicating potential growth fueled by revenue leverage and strategic initiatives such as Ignite.

The company's Ignite plan focuses on driving growth through innovation, simplifying processes with a customer-first approach, and improving operational productivity. Furthermore, Cramer also highlighted the companys recent reorganization. Acknowledging that the analyst day did not lead to much stock activity, Cramer said:

Now, the analyst day didn't have much impact on the stock, but I think it was a good reintroduction for this fine company which might have fallen off investors radar during this listless period for the life science space.

In November, the company announced the new organizational structure to improve collaboration and better align with customer needs. The three business groups include Life Sciences and Diagnostics Markets Group (LDG), representing 38% of revenue, which focuses on pharma, biopharma, clinical, and diagnostics markets.

The Applied Markets Group (AMG), accounting for 20% of revenue, serves industries such as food, environmental, forensics, and chemicals. The Agilent CrossLab Group (ACG), making up 42% of revenue, supports all end markets by strengthening customer connections and providing services, software, and consumables.

Overall A ranks 3rd on our list of stocks on Jim Cramer's radar. While we acknowledge the potential of A as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than A but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.

Disclosure: None. This article is originally published at Insider Monkey.

Error fetching the URL: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4746771-dividend-champion-contender-and-challenger-highlights-w eek-of-december-29nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

A month has gone by since the last earnings report for Agilent Technologies (A). Shares have added about 1.3% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Agilent Technologies reported fourth-quarter fiscal 2024 earnings of $1.46 per share, which beat the Zacks Consensus Estimate by 3.6%. The figure increased 5.8% year over year.Revenues of $1.70 billion surpassed the Zacks Consensus Estimate by 1.67%. The top line increased 0.8% on a reported basis and moved down 0.3% on a core basis from the year-ago quarter.This growth was driven by advancements in the Pharmaceutical, Diagnostics and Clinical sectors, along with improvements in the Chemical and Advanced Materials markets.However, the company faced challenges in the Food, Academic and Government, and Environmental and Forensics markets in the reported quarter.Modest weakening conditions in the Americas and China region were significant headwinds, whereas growing momentum across Europe and the Asia Pacific provided a tailwind.

Agilent currently has three reporting segments Life Sciences & Applied Markets Group (LSAG), Agilent Cross Lab Group (ACG), and Diagnostics and Genomics Group (DGG).LSAG: The segment generated $833 million or 49% of the companys total revenues. This marked a 1% decline both on a reported and core basis compared with the prior-year quarter. This was due to softness in the instrument business as customers took a cautious approach toward capital expenditures. However, this was offset by strong demand for analytical lab consumables, which demonstrated mid-single-digit growth or better across all end markets and regions.ACG: Revenues from the segment were $426 million, accounting for 25% of the total revenues. The top line grew 5% on a reported basis and 5% on a core basis compared with the prior-year quarter. This was driven by strong growth in contract business, including the fast-expanding Enterprise Services segment, which posted double-digit growth in the reported quarter. ACG achieved growth in all markets and regions except China, which was flat year over year but improved sequentially.DGG: Revenues decreased 1% year over year on a reported and 3% on a core basis to $442 million, accounting for the remaining 26% of the total revenues. This was led by expected softness in Cell Analysis and NASD, partially offset by strong high-single-digit growth in the Cancer Dx business and improved results in Genomics.The company recently unveiled a new organizational structure, aimed at accelerating its operational transformation and driving higher growth through a market-focused, customer-centric strategy. The new structure includes the Life Sciences and Diagnostics Markets Group (LDG), Applied Markets Group (AMG) and Agilent Cross Lab Group (ACG).

For the fourth quarter of 2024, the gross margin in the LSAG segment contracted 40 basis points (bps) to 59.1% from the prior-year quarter. ACGs gross margin expanded 50 bps to 50.9%. DGGs gross margin contracted 220 bps year over year to 51.5%.Research and development (R&D) expenses on a non-GAAP basis were $109 million, down 6% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose slightly to $362 million, marking a 1.4% increase from the prior-year quarter.As a percentage of revenues, R&D expenses fell 50 bps year over year to 6.4%, whereas SG&A expenses grew 10 bps year over year to 21.3%.The non-GAAP operating margin of 27.4% for the fiscal fourth quarter of 2024 indicates a year-over-year contraction of 40 bps.Segment-wise, the operating margin in the LSAG segment declined 60 bps to 28% from the prior-year quarter. ACGs operating margin fell 180 bps year over year to 32.6%. Meanwhile, the DGGs operating margin contracted 140 bps year over year to 21.3%.

As of Oct. 31, 2024, Agilents cash and cash equivalents were $1.33 billion, down from $1.78 billion as of July 31, 2024.Accounts receivables were $1.32 billion at the end of the fourth quarter of fiscal 2024 compared with $1.23 billion at the end of the third quarter.The long-term debt was $3.35 billion for the reported quarter compared with $2.14 billion in the prior quarter.Cash flow from operating activities was $481 million in the fourth quarter of fiscal 2024 compared with $452 million in the previous quarter.

For the first quarter of fiscal 2025, management expects revenues of $1.650-$1.680 billion, indicating a decline of 0.5% against an increase of 1.3% on a reported basis and a decrease of 2% versus a rise of 0.2% on a core basis from the year-ago quarters actuals.Non-GAAP fiscal first-quarter earnings per share are expected to be $1.25-$1.28.For fiscal 2025, management revised its revenue guidance from $6.45-$6.50 billion to $6.79-$6.87 billion, implying an increase of 4.3-5.5% on a reported basis and 2.5-3.5% on a core basis from the fiscal 2024 reported figure.The company also revised fiscal 2025 non-GAAP earnings per share guidance from $5.21-$5.25 to $5.54-$5.61.

It turns out, estimates revision have trended downward during the past month.

The consensus estimate has shifted -8.21% due to these changes.

Currently, Agilent has an average Growth Score of C, though it is lagging a bit on the Momentum Score front with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.

Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Agilent has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.

Zacks Investment Research

Investors in Agilent Technologies, Inc. A need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $80.00 Call had some of the highest implied volatility of all equity options today.

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

Clearly, options traders are pricing in a big move for Agilent shares, but what is the fundamental picture for the company? Currently, Agilent is a Zacks Rank #4 (Sell) in the Electronics - Testing Equipment industry that ranks in the Bottom 34% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while four have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from earnings of $1.38 per share to $1.27 in that period.Given the way analysts feel about Agilent right now, this huge implied volatility could mean theres a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Error fetching the URL: 401 Client Error: HTTP Forbidden for url:

https://www.marketwatch.com/data-news/agilent-technologies-inc-stock-rises-friday-still-underperforms-market-2fbe1176-235eafd36509

Stock Detailsmeta:

version: v1.0
status: 200
copywrite: https://apicalls.io
symbol: Quotes Data
processedTime: 2025-01-12T05:05:55.927595Z
body:
- Item 1:
preMarketChange: None
preMarketChangePercent: None
preMarketPrice: None
preMarketTime: None
postMarketChange: 0.179993
postMarketChangePercent: 0.0759944
postMarketPrice: 237.03
postMarketTime: 1736557190
language: en-US
region: US
quoteType: EQUITY
typeDisp: Equity
quoteSourceName: Nasdaq Real Time Price
triggerable: True
customPriceAlertConfidence: HIGH
currency: USD
hasPrePostMarketData: True

firstTradeDateMilliseconds: 345479400000

priceHint: 2

regularMarketChange: -5.849991

regularMarketDayHigh: 240.15

regularMarketDayRange: 233.0 - 240.15

regularMarketDayLow: 233

regularMarketVolume: 58293813

regularMarketPreviousClose: 242.7

bid: 223.29

ask: 247.42

bidSize: 1

askSize: 1

fullExchangeName: NasdaqGS

financialCurrency: USD

regularMarketOpen: 240.025

averageDailyVolume3Month: 45067829

averageDailyVolume10Day: 42582530

fiftyTwoWeekLowChange: 72.770004

fiftyTwoWeekLowChangePercent: 0.4435032

fiftyTwoWeekRange: 164.08 - 260.1

fiftyTwoWeekHighChange: -23.25

fiftyTwoWeekHighChangePercent: -0.08938869

fiftyTwoWeekLow: 164.08

fiftyTwoWeekHigh: 260.1

fiftyTwoWeekChangePercent: 28.982199

dividendDate: 1731542400

longName: Apple Inc.

regularMarketChangePercent: -2.4103794

regularMarketPrice: 236.85

earningsTimestamp: 1738270800

earningsTimestampStart: 1738270800

earningsTimestampEnd: 1738270800

earningsCallTimestampStart: 1738274400

earningsCallTimestampEnd: 1738274400

isEarningsDateEstimate: False

trailingAnnualDividendRate: 0.98

trailingPE: 38.891624

dividendRate: 1

trailingAnnualDividendYield: 0.004037907

dividendYield: 0.42

epsTrailingTwelveMonths: 6.09

epsForward: 8.31

epsCurrentYear: 7.39695

priceEpsCurrentYear: 32.019955

sharesOutstanding: 15115799552

bookValue: 3.767

fiftyDayAverage: 238.7128

fiftyDayAverageChange: -1.862793

fiftyDayAverageChangePercent: -0.00780349

twoHundredDayAverage: 215.46355

twoHundredDayAverageChange: 21.38646

twoHundredDayAverageChangePercent: 0.0992579

marketCap: 3580177154048

forwardPE: 28.501804

priceToBook: 62.87497

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 1.9 - Buy

tradeable: False

cryptoTradeable: False

marketState: CLOSED

shortName: Apple Inc.

corporateActions:

regularMarketTime: 1736542802

exchange: NMS

messageBoardId: finmb_24937

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

esgPopulated: False

displayName: Apple

symbol: AAPL

nstock news

Published: 2025-01-11 20:31:13 ET

AAPL

(Reuters) - Apple's board of directors recommended investors vote against a shareholder proposal to abolish the company's Diversity, Equity, and Inclusion (DEI) programs, according to a proxy filing from the company.

The National Center for Public Policy, a conservative think tank, submitted a proposal that the company consider abolishing its "Inclusion & Diversity program, policies, department and goals."

The proposal cited recent Supreme Court decisions, and made the argument that DEI poses "litigation, reputational and financial risks to companies" and could make Apple more vulnerable to lawsuits.

Apple responded that it had a well-established compliance program and the proposal was unnecessary. It added that the shareholder proposal was an inappropriate attempt to micromanage Apple's business strategy.

"Apple is an equal opportunity employer and does not discriminate in recruiting, hiring, training, or promoting on any basis protected by law", the iPhone maker said in the filing. The news was first reported by TechCrunch.

Several major companies including Meta and Amazon are winding down diversity programs ahead of Republican Donald Trump's return to the U.S. presidency as conservative opposition to such initiatives grows louder.

Conservative groups have denounced DEI programs and threatened to sue companies over them, emboldened by a U.S. Supreme Court ruling in 2023 that struck down affirmative action in university admissions decisions.

The changes show how some of America's biggest businesses have reacted to a larger conservative backlash against diversity initiatives, which multiplied after widespread protests following the police killings of George Floyd and other Black Americans in 2020.

(Reporting by Chandni Shah in Bengaluru)nstock news

Vladimir Zakharov

Vladimir Zakharov

Friends, each week I set out to research and write the best, most informative, most actionable article I can deliver to my fellow dividend investors.

I'm aware of the magnitude of content on the Internet geared to

This article was written by

Austin Rogers is a REIT specialist with a professional background in commercial real estate. He writes about high-quality dividend growth stocks with the goal of generating the safest growing passive income stream possible. Since his ideal holding period is "lifelong," his focus is on portfolio income growth rather than total returns.

Analystâ€™s Disclosure: I/we have a beneficial long position in the shares of ADC, AMH, AMT, ARTNA, CTRE, EGP, HASI, MAA, NEE, REXR, VICI, WTRG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Dilok Klaisataporn/iStock via Getty Images

Dilok Klaisataporn/iStock via Getty Images

To earn a decent income from your savings has been a challenge for retirees for the past two decades. For almost a decade, the interest rates remained either zero or near zero. Only recently, in the last couple

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. This includes two High-Income portfolios, two DGI portfolios, and a conservative NPP strategy portfolio with low drawdowns and high growth. For more details or a two-week free trial, please click here.

This article was written by

Financially Free Investor is a financial writer with 25 years investment experience. He focuses on investing in dividend-growing stocks with a long-term horizon. He applies a unique 3-basket investment approach that aims for 30% lower drawdowns, 6% current income, and market-beating growth on a long-term basis and he focuses on dividend-growing stocks with a long-term horizon.

Analystâ€™s Disclosure: I/we have a beneficial long position in the shares of ABT, ABBV, CI, JNJ, PFE, NVS, NVO, AZN, UNH, CL, CLX, UL, NSRGY, PG, TSN, ADM, BTI, MO, PM, KO, PEP, EXC, D, DEA, DEO, ENB, MCD, BAC, PRU, UPS, WMT, WBA, CVS, LOW, AAPL, IBM, CSCO, MSFT, INTC, T, VZ, CVX, XOM, VLO, ABB, ITW, MMM, LMT, LYB, RIO, O, NNN, WPC, ARCC, ARDC, AWF, CII, CHI, DNP, PEO, USA, UTF, UTG, RFI, RNP, RQI, EVT, EOS, FFC, GOF, TLT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: The information presented in this article is for informational purposes only and in no way should be construed as financial advice or recommendation to buy or sell any stock. The author is not a financial advisor. Please always do further research and do your own due diligence before making any investments. Every effort has been made to present the data/information accurately; however, the author does not claim 100% accuracy. The stock portfolios presented here are model portfolios for demonstration purposes. For the complete list of our LONG positions, please see our profile on Seeking Alpha.

nstock news

Published: 2025-01-11 06:08:41 ET

AAPL

WASHINGTON (Reuters) - The lawyer for TikTok and its Chinese parent company ByteDance offered a warning during Supreme Court arguments over a law that would compel the sale of the short-video app or ban it in the United States: If Congress could do this to TikTok, it could come after other companies, too.

The law, which was the subject of arguments before the nine justices on Friday, sets a Jan. 19 deadline for ByteDance to sell the popular social media platform or face a ban on national security grounds. The companies have sought, at the very least, a delay in implementation of the law, which they say violates the U.S. Constitution's First Amendment protection against government abridgment of free speech.

Noel Francisco, representing TikTok and ByteDance, argued that Supreme Court endorsement of this law could enable statutes targeting other companies on similar grounds.

"AMC movie theaters used to be owned by a Chinese company. Under this theory, Congress could order AMC movie theaters to censor any movies that Congress doesn't like or promote any movies that Congress wanted," Francisco told the justices.

The justices signaled through their questions during the arguments that they were inclined to uphold the law, although some expressed serious concerns about its First Amendment implications.

TikTok is a platform used by about 170 million people in the United States, roughly half the country's population. Congress passed the measure last year with overwhelming bipartisan support, as lawmakers cited the risk of the Chinese government exploiting TikTok to spy on Americans and carry out covert influence operations.

Jeffrey Fisher, the lawyer representing TikTok content creators who also have challenged the law, noted during the Supreme Court arguments that Congress with this measure was focusing on TikTok and not major Chinese online retailers including Temu.

"Would a Congress (that is) really worried about these very dramatic risks leave out an e-commerce site like Temu that has 70 million Americans using it?" Fisher asked. "It's very curious why you just single out TikTok alone and not other companies with tens of millions of people having their own data taken, you know, in the process of engaging with those websites and equally, if not more, available to Chinese control."

Democratic President Joe Biden signed the measure into law and his administration is defending it in this case. The deadline for divestiture is just one day before Republican Donald Trump, who opposes the ban, takes office as Biden's successor.

'FOREIGN ADVERSARIES'

Solicitor General Elizabeth Prelogar, arguing for the Biden administration in defending the law, said it was crucial that it take effect on Jan. 19 as scheduled in order to force ByteDance to act on divestiture.

"Foreign adversaries do not willingly give up their control over this mass communications channel in the United States," Prelogar said.

"When push comes to shove, and these restrictions take effect, I think it will fundamentally change the landscape with respect to what ByteDance is willing to consider. And it might be just the jolt that Congress expected the company would need to actually move forward with the divestiture process," Prelogar said.

If the ban takes affect on Jan. 19, Apple and Alphabet's Google would no longer be able to offer

TikTok for downloads for new users but existing users could still access the app. The U.S. government and TikTok agree that app would degrade and eventually become unusable over time because companies would not be able to offer supporting services.

The Supreme Court also debated whether the possibility of TikTok being used for covert influence campaigns or propaganda purposes by China justified the banning it.

"Look, everybody manipulates content," Francisco told the court. "There are lots of people who think CNN, Fox News, the Wall Street Journal, the New York Times are manipulating their content. That is core protected speech."

Trump on Dec. 27 urged the court to put a hold on the Jan. 19 deadline to give his incoming administration "the opportunity to pursue a political resolution of the questions at issue in the case."

Under the law, the U.S. president has the power to extend the Jan. 19 deadline for 90 days, but under circumstances that do not appear to apply to the current situation in which ByteDance has made no apparent effort to sell TikTok's U.S. assets. The law mandates that the president certify that significant progress has been made toward a sale, with binding legal agreements.

Regardless, Trump does not become president until after the deadline - though Francisco said "we might be in a different world" once Trump is back in the White House.

Justice Brett Kavanaugh asked Prelogar whether the president could "say that we're not going to enforce this law?"

"I think as a general matter, of course the president has enforcement discretion," Prelogar said.

"Again, that's one of the reasons why I think it makes perfect sense to issue a preliminary injunction here and simply buy everybody a little breathing space," Francisco said.

(Reporting by David Shepardson; Editing by Will Dunham)

By David Shepardsonnstock news

Error fetching the URL: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4748878-xlg-outperforms-the-s-and-p500-indexnstock news

We are experiencing some temporary issues. The market data on this page is currently delayed.

Please bear with us as we address this and restore your personalized lists.

(Bloomberg) -- Apple Inc. disclosed a 18% pay increase for Chief Executive Officer Tim Cook ahead of its annual meeting next month, while also saying it opposed a shareholder measure calling for an end to the companys diversity program.

Most Read from Bloomberg

What Robotaxis Brought San Francisco

A Blueprint for Better Bike Lanes

Ambitious High-Speed Rail Plans Advance in the Baltic Region

NYC Condo Owners May Bear Costs of Landmark Green Building Law

Dutch Central Bank Restores Amsterdams Ugliest Building

Cooks compensation grew to $74.6 million in 2024, compared with $63.2 million the prior year, Apple said in its annual proxy filing on Friday. In addition to executive compensation, investors will vote on four outside proposal at the meeting on Feb. 25. The company opposed all of them.

The measure about Apples diversity, equity and inclusion, or DEI, efforts urged the company to consider abolishing the program because it may discriminate against employees and draw lawsuits. The company said the proposal was an inappropriate attempt to restrict Apples business operations and that it already assesses legal and regulatory risks.

Cooks pay was made up of a $3 million base salary, $58.1 million in stock awards, and roughly $13.5 million in additional compensation. The raise mostly comes from an increase in stock award value.

While Cooks pay is up significantly from last year, its still a far cry from his total compensation in 2022, which reached nearly $100 million thanks to stock awards. His pay was cut at his discretion in 2023 after pushback from employees and shareholders.

Apples board of directors said it made no changes to the amount or structure of Mr. Cooks 2025 total target compensation.

Other executives, including Apples retail chief, former chief financial officer, chief operating officer and general counsel, all made more than $27 million in 2024, representing slight increases from the prior year. Luca Maestri, the ex-CFO, was recently replaced as by Kevan Parekh.

Most Read from Bloomberg Businessweek

He Built Russias Biggest Tech Company. Now Hes Starting OverWithout Putin

The US Government Is Sitting on a Possible Solution to the Housing Crisis

What Happens When TikToks Trend Machine Shuts Down?

Musk Tries to Pick a Fight with the UK

Israels Wartime Farmers Are Relearning How to Plow Without GPS

Sign in to access your portfolionstock news

Error fetching the URL: 404 Client Error: Not Found for url: https://finance.yahoo.com/m/f8950c0e-7669-39cd-9e7d-be81d3956c93/hershey-ceo-michele-buck-to.htmlnstock news

Error fetching the URL: 404 Client Error: Not Found for url: https://finance.yahoo.com/m/7d026465-47c7-3f98-8601-7e2ab779425f/funds-bet-on-apple%2C-google.htmlnstock news

The clock is ticking for TikTok. The Chinese-owned video-sharing platform used by nearly half the country could disappear from U.S. app stores later this month under a new security law. On Friday, TikTok argued its case before the Supreme Court.

Sign in to access your portfolionstock news

If sentiment is anything to go by, the Magnificent 7 stocks, led by Apple Nvidia and Microsoft are set to be replaced by a movie that may or may not be equally goodBATMMAAN. While cute names are fun to write about, theyre a lousy way to organize a stock portfolio. Think of it as the DC comics superhero spelled by a toddler.

Sign in to access your portfolio

Stock Detailsmeta:

version: v1.0

status: 200

copywrite: https://apicalls.io

symbol: Quotes Data

processedTime: 2025-01-12T05:06:19.470113Z

body:

- Item 1:

preMarketChange: None

preMarketChangePercent: None

preMarketPrice: None

preMarketTime: None

postMarketChange: -0.19998169

postMarketChangePercent: -0.042726565

postMarketPrice: 467.85

postMarketTime: 1736557200

language: en-US

region: US

quoteType: EQUITY

typeDisp: Equity

quoteSourceName: Delayed Quote

triggerable: True

customPriceAlertConfidence: HIGH

currency: USD

marketState: CLOSED

shortName: Lockheed Martin Corporation

longName: Lockheed Martin Corporation

hasPrePostMarketData: True

firstTradeDateMilliseconds: 221149800000

priceHint: 2

regularMarketChange: -0.800018

regularMarketDayHigh: 471.59

regularMarketDayRange: 465.73 - 471.59

regularMarketDayLow: 465.73

regularMarketVolume: 952664

regularMarketPreviousClose: 468.85

bid: 467.01

ask: 471.8

bidSize: 8

askSize: 18

fullExchangeName: NYSE

corporateActions:

regularMarketTime: 1736542802

exchange: NYQ

messageBoardId: finmb_285827

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

esgPopulated: False

regularMarketChangePercent: -0.170634

regularMarketPrice: 468.05

marketCap: 110944231424

forwardPE: 16.650658

priceToBook: 15.341877

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 2.3 - Buy

financialCurrency: USD

regularMarketOpen: 468

averageDailyVolume3Month: 1213218

averageDailyVolume10Day: 997440

fiftyTwoWeekLowChange: 54.129974

fiftyTwoWeekLowChangePercent: 0.13077399

fiftyTwoWeekRange: 413.92 - 618.95

fiftyTwoWeekHighChange: -150.90002

fiftyTwoWeekHighChangePercent: -0.24380001

fiftyTwoWeekLow: 413.92

fiftyTwoWeekHigh: 618.95

fiftyTwoWeekChangePercent: 2.2300363

dividendDate: 1735257600

earningsTimestamp: 1738071000

earningsTimestampStart: 1738071000

earningsTimestampEnd: 1738071000

earningsCallTimestampStart: 1738080000

earningsCallTimestampEnd: 1738080000

isEarningsDateEstimate: False

trailingAnnualDividendRate: 12.6

trailingPE: 16.95219

dividendRate: 13.2

trailingAnnualDividendYield: 0.026874267

dividendYield: 2.82

epsTrailingTwelveMonths: 27.61

epsForward: 28.11

epsCurrentYear: 26.77688

priceEpsCurrentYear: 17.479631

sharesOutstanding: 237035008

bookValue: 30.508

fiftyDayAverage: 515.6688

fiftyDayAverageChange: -47.618835

fiftyDayAverageChangePercent: -0.09234383

twoHundredDayAverage: 512.7632

twoHundredDayAverageChange: -44.713196

twoHundredDayAverageChangePercent: -0.08720048

tradeable: False

cryptoTradeable: False

displayName: Lockheed Martin

symbol: LMT

nstock news

Sundry Photography

If you think technical analysis is silly, thanks for reading this far. Now, you might want to exit. I aim to educate, and when I see the charts speak to me as they are doing now for aerospace giant Lockheed Martin Corp. (

experience.Â

24/7 access to Sungardenâ€™s investment research deck

Bottom-line analysis of stocks, ETFs, and option strategies

Trade alerts and rationale, delivered in real-time

Proprietary educational content

You wonâ€™t get: sales pitches, outlandish claims, greed-driven speculation

This article was written by

Analystâ€™s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.nstock news

Dilok Klaisataporn/iStock via Getty Images

Dilok Klaisataporn/iStock via Getty Images

To earn a decent income from your savings has been a challenge for retirees for the past two decades. For almost a decade, the interest rates remained either zero or near zero. Only recently, in the last couple

High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. This includes two High-Income portfolios, two DGI portfolios, and a conservative NPP strategy portfolio with low drawdowns and high growth. For more details or a two-week free trial, please click here.

This article was written by

Financially Free Investor is a financial writer with 25 years investment experience. He focuses on investing in dividend-growing stocks with a long-term horizon. He applies a unique 3-basket investment approach that aims for 30% lower drawdowns, 6% current income, and market-beating growth on a long-term basis and he focuses on dividend-growing stocks with a long-term horizon.

Analystâ€™s Disclosure: I/we have a beneficial long position in the shares of ABT, ABBV, CI, JNJ, PFE, NVS, NVO, AZN, UNH, CL, CLX, UL, NSRGY, PG, TSN, ADM, BTI, MO, PM, KO, PEP, EXC, D, DEA, DEO, ENB, MCD, BAC, PRU, UPS, WMT, WBA, CVS, LOW, AAPL, IBM, CSCO, MSFT, INTC, T, VZ, CVX, XOM, VLO, ABB, ITW, MMM, LMT, LYB, RIO, O, NNN, WPC, ARCC, ARDC, AWF, CII, CHI, DNP, PEO, USA, UTF, UTG, RFI, RNP, RQI, EVT, EOS, FFC, GOF, TLT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: The information presented in this article is for informational purposes only and in no way should be construed as financial advice or recommendation to buy or sell any stock. The author is not a financial advisor. Please always do further research and do your own due diligence before making any investments. Every effort has been made to present the data/information accurately; however, the author does not claim 100% accuracy. The stock portfolios presented here are model portfolios for demonstration purposes. For the complete list of our LONG positions, please see our profile on Seeking Alpha.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.nstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Lockheed Martin Corp.s LMT business unit, Aeronautics, recently clinched a modification contract for the F-35 fighter aircraft. The award has been offered by the Naval Air Systems Command, Patuxent River, MD.

Valued at $41.6 million, the contract is expected to be completed by March 2028. Per the terms of the deal, Lockheed will procure engineering, integration support, hardware, and installation support for flight test instrumentation modifications to F-35 production aircraft.

The majority of work related to this deal will be carried out in Fort Worth, TX.

Global defense spending has surged as nations strengthen their military capabilities, driving demand for advanced weaponry like fighter jets, which are essential for air combat. This trend has significantly benefited Lockheed, a leading manufacturer of combat aircraft, through steady orders from the Pentagon and U.S. allies.

Lockheeds F-35 fighter jet, renowned as the most advanced fifth-generation aircraft, stands out for its mission readiness and cutting-edge technology. Equipped with advanced sensors and communication systems, the F-35 seamlessly connects air, land, sea, space and cyber domains, enhancing situational awareness.

These exceptional features have fueled strong demand for this jet. As of Sept. 30, 2024, Lockheed had delivered 1,040 F-35 aircraft since the program's inception. The recent contract win underscores the sustained popularity of the F-35 in the global combat jet market, further solidifying its position as a cornerstone of modern air defense systems.

Rising military conflicts, terrorism and border disputes, along with rapid technological advancements in combat jets, have led nations to increase their defense spending on combat-proven jets, which constitute an integral part of their defense structure.

This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 3.7% for the global fighter aircraft market during the 2024-2029 period.

Such strong market prospects drive growth opportunities for Lockheed, backed by its robust portfolio of combat jets, including the F-16, F-22 and F-21 aircraft, in addition to the F-35 jet.

Other defense companies that are likely to benefit from the expanding global fighter aircraft market are discussed below.

Northrop Grumman Corporation NOC: It is a leading provider of manned and unmanned air systems. It builds some of the worlds most advanced aircraft, such as the E-2C Hawkeye 2000, A-10 Thunderbolt II, F-5 Tiger Fighter Jet and many more.

Northrop has a long-term (three to five years) earnings growth rate of 19%. The Zacks Consensus Estimate for NOCs 2025 sales indicates growth of 3.4% from the year-ago estimated figure.

Embraer ERJ: The company offers a comprehensive portfolio of the most advanced aircraft in the combat market, which includes the A-29 Super Tucano light attack and advanced trainer and the C-390 Millennium military multi-mission aircraft.

The Zacks Consensus Estimate for ERJs 2025 sales indicates growth of 18.3% from the prior-year estimated number. The stock boasts a solid average earnings surprise of 127.28% for the trailing four quarters.

Textron TXT: Its Textron Aviation Defense unit offers the largest and most successful flight training system in the world. Textron Aviation Defenses portfolio includes the Beechcraft AT-6E Wolverine jet, which covers a wide-mission spectrum including training, manned Intelligence Surveillance and Reconnaissance as well as light precision attack.

Textron has a long-term earnings growth rate of 10.1%. The Zacks Consensus Estimate for TXTs 2025 sales indicates growth of 7.4% from the year-ago estimated figure.

Shares of LMT have gained 1.7% in the past six months against the industrys 0.9% decline.

Image Source: Zacks Investment Research

LMT currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1

Rank (Strong Buy) stocks here.

RTX Corporations RTX unit, Raytheon, recently secured a $333.3 million contract for facilitating the full-rate production of Standard Missile-6 (SM-6). RTX will also supply spares and a round design agent for SM-6 under this agreement.

The majority of the work related to this contract will be performed in Tucson, AZ, and Huntsville, AL. This contract is projected to be completed by October 2027.The award has been provided by the Naval Sea Systems Command, Washington, D.C. This contract includes options that, if exercised, will bring the total value of the agreement to $908.1 million.

With countries worldwide enhancing their defense capabilities, spending on advanced military arms and ammunition, including missiles and missile systems, has been rapidly increasing. RTX, as a prominent manufacturer of missile systems, has been benefiting from a steady flow of orders from the Pentagon and other U.S. allies. The recent contract is an example of that.RTX's SM-6 missile is an advanced and versatile defense system for naval ships. It can handle multiple missions, including defending against air attacks, surface threats and ballistic missiles, making it highly effective in protecting fleets. Its advanced design combines reliable technology to provide strong and cost-effective defense for the U.S. Navy and its allies.Such impressive features of this missile must have enabled the company to deliver more than 500 of SM-6 missiles to the U.S. Navy, which reflects the solid demand it enjoys in the missile market.

Rising military conflicts, terrorism and border disputes have led nations to increase their focus on national security, particularly on missile defense systems in recent times, backed by the rapid development of advanced missile technologies over the last decade.This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 5% for the global missiles and missile defense system market during the 2025-2030 period.Such massive growth projections offer a strategic advantage to RTX, which has a handful of combat-proven missiles in its product portfolio, like the TOW missile, Guidance Enhanced Missile, Advanced Medium Range Air-to-Air Missile, Tomahawk, Standard Missile 2 and a few more, in addition to the SM-6.

Other defense companies that are likely to enjoy the perks of the expanding missiles and missile system market have been discussed below:Northrop Grumman NOC: Northrop Grumman provides high-speed, long-range strike weapons like the AARGM-ER, which is a supersonic, air-launched tactical missile system. It also develops and builds advanced missile defense technology, ranging from command systems to directed energy weapons, advanced munitions and powerful sensors.The companys long-term (three to five years) earnings growth rate is 19%. The Zacks Consensus Estimate for NOCs 2025 sales indicates year-over-year growth of 3.4%.The Boeing Company BA: It manufactures various missile defense systems, including the Ground-based Midcourse Defense, Aegis Ballistic Missile Defense and Avenger. Boeing-built and supported air and missile defense systems have been protecting its customers for nearly 25 years against threats ranging from intercontinental ballistic missiles to hostile aircraft.The company has a long-term earnings growth rate of 19.3%. The Zacks Consensus Estimate for BAs 2025 sales indicates year-over-year growth of 22.1%.Lockheed Martin LMT: Lockheed Martins missile defense program includes the Patriot Advanced Capability-3 and Terminal High-Altitude Area Defense air and missile defense programs. It also manufactures the Multiple Launch Rocket System, the Joint Air-to-Surface Standoff Missile and Javelin tactical missile programs alongside other tactical missiles.The company has a long-term earnings growth rate of 4.4%. The Zacks Consensus Estimate for LMTs 2025 sales indicates year-over-year growth of 4.1%.

RTX shares have risen 15.2% in the past six months against the industrys 0.9% decline.

Image Source: Zacks Investment Research

RTX currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Lockheed Martin (LMT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this aerospace and defense company have returned -7%, compared to the Zacks S&P 500 composite's -2.7% change. During this period, the Zacks Aerospace - Defense industry, which Lockheed falls in, has lost 2.3%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Here at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

Lockheed is expected to post earnings of $6.58 per share for the current quarter, representing a year-over-year change of -16.7%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.2%.

The consensus earnings estimate of $26.68 for the current fiscal year indicates a year-over-year change of -4.1%. This estimate has changed -0.1% over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $28.03 indicates a change of +5.1% from what Lockheed is expected to report a year ago. Over the past month, the estimate has changed -0.1%.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Lockheed.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.

For Lockheed, the consensus sales estimate for the current quarter of $18.85 billion indicates a year-over-year change of -0.1%. For the current and next fiscal years, $71.27 billion and $74.17

billion estimates indicate +5.5% and +4.1% changes, respectively.

Lockheed reported revenues of $17.1 billion in the last reported quarter, representing a year-over-year change of +1.3%. EPS of $6.84 for the same period compares with $6.77 a year ago.

Compared to the Zacks Consensus Estimate of $17.28 billion, the reported revenues represent a surprise of -1.05%. The EPS surprise was +5.72%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial to determine whether its current price correctly reflects the intrinsic value of the underlying business and the company's growth prospects.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Lockheed is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Lockheed. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

To read this article on Zacks.com click here.

Zacks Investment Research

Sign in to access your portfolionstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Airbus SE EADSY secured a contract to provide logistics support and engineering services for the UH-72 Lakota helicopter. The award has been offered by the Army Contracting Command, Redstone Arsenal, AL.Valued at $315 million, the contract is expected to be completed by Dec. 31, 2025. The majority of the work related to this deal will be carried out in Grand Prairie, TX.

As nations are upgrading their defense capabilities, expenditures on cutting-edge defense equipment and ammunition have been rising quickly. Increasing expenditures on military helicopters, which are essential for air combat operations, contribute to the rising defense expenditures. As a leading manufacturer of combat helicopters, Airbus has received a steady stream of orders from all over the world.More than 140 armed forces worldwide rely on Airbus for its expertise to produce high-quality multi-role helicopters. These copters are able to fulfill a wide range of operational military roles, such as armed reconnaissance, utility, attack, naval, maritime and special operations.In particular, EADSYs UH-72 Lakota is a highly adaptable and reconfigurable helicopter capable of carrying out a wide range of tasks under a variety of climates and environments. Its missions are as diverse as its operational locations, encompassing training, general utility, search and rescue, reconnaissance, medical evacuation, disaster response, homeland security, counterdrug, command and control, and VIP transportation.

Amid rising military conflicts, terrorism and border disputes, these combat-proven helicopters play a critical role in a country's security system. This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 2.9% for the military helicopter market during the 2024-2030 period. Such growth opportunities offered by the aforementioned market should bode well for Airbus.EADSYs product portfolio consists of varied combat helicopters, such as the H125M, H160M, H175M, H215M, H225M, Tiger, NH90 and a few more. These enjoy solid demand in the global military helicopter market, with some 19,000 helicopters delivered across 150 nations.

Other defense companies that are expected to enjoy the perks of the expanding military helicopter market have been discussed below:Boeing BA: The companys helicopters are renowned for their leading-edge, relevant solutions that provide capacity. Boeings product portfolio includes combat helicopters and rotorcraft like the H-47 Chinook, AH-64 Apache, AH-6 Little Bird and V-22 Osprey.Boeing has a long-term (three to five years) earnings growth rate of 19.3%. The Zacks Consensus Estimate for BAs 2025 sales indicates an improvement of 21.9% from the 2024 estimated figure.Textron TXT: Its Bell business segment supplies advanced military helicopters and provides parts and support services to the U.S. Government and military customers outside the United States. Its portfolio of combat helicopters includes Bell 412M, Bell 429M, Bell 407M and Bell 505M. TXT boasts a long-term earnings growth rate of 10.1%. The Zacks Consensus Estimate for TXTs 2025 sales indicates year-over-year growth of 7.4% from the 2024 estimated figure.Lockheed Martin LMT: Its Sikorsky business unit provides military and rotary-wing aircraft to all five branches of the U.S. armed forces, along with military services and commercial operators in 40 nations. Some of LMTs renowned products are Armed Black Hawk, CH-53K, MH-60R SEAHAWK, Raider X, S-97 Raider, S-70 BLACK Hawk, etc.Lockheed boasts a long-term earnings growth rate of 4.4%. The Zacks Consensus Estimate for LMTs 2025 sales indicates an improvement of 3.9% from the 2024 estimated figure.

In the past six months, Airbus shares have risen 13.1% compared to the industrys fall of 1.7%.

Image Source: Zacks Investment Research

Airbus currently carries a Zacks Rank #4 (Sell).You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Airbus Group (EADSY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Sign in to access your portfolionstock news

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

Lockheed Martin Corporations LMT Aeronautics business segment recently clinched a modification contract to support the F-35 Joint Strike Fighter aircraft program. The award has been provided by the Naval Air Systems Command, Patuxent River, MD.

Valued at $678.4 million, the contract is expected to be completed by December 2028. Per the terms of the deal, Lockheed will provide various material modification kits, special test and tooling equipment, and associated seed assets to support the F-35 Joint Strike Fighter aircraft.The contract will serve the U.S. Navy, Air Force, Marine Corps and non-Department of Defense participants. The work related to this deal will be executed in Fort Worth, TX.

The F-35 program is widely recognized as the most advanced 5th-generation fighter jet, offering unmatched mission readiness. With cutting-edge sensors and communication systems, the F-35 is designed to operate seamlessly across multiple domains.These exceptional features must have been driving significant demand for the F-35 jets. This jet programs demand trend can be gauged from the fact that since its launch, Lockheed has delivered 1,040 units as of Sept. 29, 2024.

Rising military conflicts, terrorism and border disputes, along with rapid technological advancements in combat jets, have led nations to increase their defense spending on combat-proven jets, which constitute an integral part of their defense structure.This is likely to have prompted the Mordor Intelligence firm to forecast a compound annual growth rate of 5.2% for the global military aviation market during the 2024-2030 period.Such strong market prospects drive growth opportunities for Lockheed Martin, backed by its robust portfolio of combat jets, including the F-16, F-22 and F-21 aircraft, in addition to the F-35 jet. Lockheed Martins total backlog was $165.69 billion as of Sept. 29, 2024.

Other defense companies that are likely to benefit from the expanding global fighter aircraft market are discussed below:Northrop Grumman Corporation NOC: Northrop provides manned and unmanned air systems. It builds some of the worlds most advanced aircraft like the E-2C Hawkeye 2000, A-10 Thunderbolt II, F-5 Tiger Fighter Jet and many more.Northrop has a long-term (three to five years) earnings growth rate of 19%. The Zacks Consensus Estimate for NOCs 2025 sales indicates year-over-year growth of 3.4%.Embraer ERJ: The company offers a comprehensive portfolio of the most advanced aircraft in the combat market, which includes the A-29 Super Tucano light attack and advanced trainer and the C-390 Millennium military multi-mission aircraft.The Zacks Consensus Estimate for ERJs 2025 sales indicates year-over-year growth of 18.3%. The company delivered an average earnings surprise of 127.28% in the last four quarters.The Boeing Company BA: Its Defense, Space & Security segment engages in the research, development, production and modification of manned and unmanned military aircraft. BAs product portfolio includes a range of combat-proven aircraft like the F/A-18 Super Hornet, P-8, C-17 Globemaster III, EA-18G and a few more.Boeing has a long-term earnings growth rate of 19.3%. The Zacks Consensus Estimate for BAs 2025 sales indicates year-over-year growth of 21.9%.

Shares of LMT have risen 2.9% in the past six months against the industrys 1% decline.

Image Source: Zacks Investment Research

LMT currently carries a Zacks Rank #3 (Hold). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Zacks Investment Research

The nations second largest airline is playing catch-up to rivals after its bet to overhaul corporate travel failed.

Sign in to access your portfolionstock news

Error fetching the URL: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4748423-lockheed-martin-recession-proof-your-portfolio-and-dividends-with-lmtnstock news

(Reuters) - Lockheed Martin delivered a total of 110 F-35 fighter jets to the United States and its allies in 2024, the Bethesda, Maryland-based defense contractor said in a statement on Wednesday.

The delivery total achieves the higher end of the range of 75 to 110 jet deliveries CEO Jim Taiclet gave in an earnings call last summer.

Lockheed lifted its sales target in July after the Pentagon resumed taking F-35 deliveries following a months-long pause on delays on its software upgrade. Lockheed has been upgrading the jets under the Technology Refresh 3, or TR-3 program, which gives the F-35 better displays and processing power.

Lockheed's F-35 program contributes around 30% of the company's revenue.

"Lockheed Martin is fully committed to advancing and delivering unmatched air dominance solutions to the United States and our allies, helping to ensure America continues to own the skies," the company said in a statement.

(Reporting by Ryan Patrick Jones and Mike Stone; editing by Diane Craft)

Stock Detailsmeta:

version: v1.0

status: 200

copywrite: https://apicalls.io

symbol: Quotes Data

processedTime: 2025-01-12T05:06:42.249428Z

body:

- Item 1:

preMarketChange: None

preMarketChangePercent: None

preMarketPrice: None

preMarketTime: None

postMarketChange: None

postMarketChangePercent: None

postMarketPrice: None

postMarketTime: None

language: en-US

region: US

quoteType: NONE

triggerable: False

customPriceAlertConfidence: NONE

corporateActions:

messageBoardId: finmb_91800

esgPopulated: False

tradeable: False

cryptoTradeable: False

hasPrePostMarketData: False

symbol: AABA

--- ACAD ---

Stock Info:

meta:

version: v1.0

status: 200

copywrite: https://apicalls.io

symbol: Quotes Data

processedTime: 2025-01-12T04:06:31.568627Z

body:

- Item 1:

preMarketChange: None

preMarketChangePercent: None

preMarketPrice: None

preMarketTime: None

postMarketChange: -0.1

postMarketChangePercent: -0.579376

postMarketPrice: 17.16

postMarketTime: 1736550694

language: en-US

region: US

quoteType: EQUITY

typeDisp: Equity

quoteSourceName: Nasdaq Real Time Price

triggerable: True

customPriceAlertConfidence: HIGH

currency: USD

esgPopulated: False

marketState: CLOSED

hasPrePostMarketData: True

firstTradeDateMilliseconds: 1085664600000

priceHint: 2

regularMarketChange: -0.34000015

regularMarketDayHigh: 17.715

regularMarketDayRange: 17.08 - 17.715

regularMarketDayLow: 17.08

regularMarketVolume: 2019460

regularMarketPreviousClose: 17.6

bid: 17.22

ask: 17.47

bidSize: 9

askSize: 23

fullExchangeName: NasdaqGS

financialCurrency: USD

regularMarketOpen: 17.23

averageDailyVolume3Month: 2303567

averageDailyVolume10Day: 6479600

fiftyTwoWeekLowChange: 3.1100006

fiftyTwoWeekLowChangePercent: 0.21978803

fiftyTwoWeekRange: 14.15 - 29.29

fiftyTwoWeekHighChange: -12.030001

fiftyTwoWeekHighChangePercent: -0.41072038

fiftyTwoWeekLow: 14.15

fiftyTwoWeekHigh: 29.29

fiftyTwoWeekChangePercent: -40.379967

earningsTimestamp: 1730927100

earningsTimestampStart: 1740481140

earningsTimestampEnd: 1741003200

earningsCallTimestampStart: 1730928600

earningsCallTimestampEnd: 1730928600

isEarningsDateEstimate: True

trailingAnnualDividendRate: 0

trailingPE: 22.128206

trailingAnnualDividendYield: 0

epsTrailingTwelveMonths: 0.78

epsForward: 0.82

epsCurrentYear: 0.69515

priceEpsCurrentYear: 24.829174

sharesOutstanding: 166392000

bookValue: 3.47

fiftyDayAverage: 16.8744

fiftyDayAverageChange: 0.38560104

shortName: ACADIA Pharmaceuticals Inc.

longName: ACADIA Pharmaceuticals Inc.

regularMarketChangePercent: -1.931819

regularMarketPrice: 17.26

corporateActions:

regularMarketTime: 1736542802

exchange: NMS

messageBoardId: finmb_683713

exchangeTimezoneName: America/New_York

exchangeTimezoneShortName: EST

gmtOffSetMilliseconds: -18000000

market: us_market

fiftyDayAverageChangePercent: 0.022851245

twoHundredDayAverage: 16.39315

twoHundredDayAverageChange: 0.8668499

twoHundredDayAverageChangePercent: 0.052878786

marketCap: 2871926016

forwardPE: 21.04878

priceToBook: 4.9740634

sourceInterval: 15

exchangeDataDelayedBy: 0

averageAnalystRating: 2.1 - Buy

tradeable: False

cryptoTradeable: False

displayName: ACADIA Pharmaceuticals

symbol: ACAD

News:

Title: Further weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) drops 5.2% this week, taking five-year losses to 61%

Source: Yahoo

Published Time: 2025-01-08 19:58:40

URL:

https://finnhub.io/api/news?id=137f499c785888596a7dcc5b5140e4db5598ad8f86e38a6a9ad6d06d98f30548

Title: ACADIA Pharmaceuticals Inc.(NasdaqGS: ACAD) added to S&P 600 Health Care

Source: Finnhub

Published Time: 2025-01-02 18:00:00

URL:

https://finnhub.io/api/news?id=f69c91fa93c40b61b8b99c8c549563353fc877449ff547f176f521ce021
31107

Title: ACADIA Pharmaceuticals Inc.(NasdaqGS: ACAD) added to S&P Composite 1500

Source: Finnhub

Published Time: 2025-01-02 18:00:00

URL:

https://finnhub.io/api/news?id=7b182971a8630feb8a85f3f0e3855ec66d5b182235c9dac9cfa277847e
6177ef

Title: ACADIA Pharmaceuticals Inc.(NasdaqGS: ACAD) added to S&P 600

Source: Finnhub

Published Time: 2025-01-02 18:00:00

URL:

https://finnhub.io/api/news?id=09e89fb773cf89fa4c26b38b5cb5cf8a63d2a6310bd46f191a8bf646e47
295b0

Title: Why ACADIA Pharmaceuticals Inc. (ACAD) Is Skyrocketing

Source: Yahoo

Published Time: 2025-01-02 07:58:59

URL:

https://finnhub.io/api/news?id=098ce4e7e98a0d7d930b4279ee70ac0aaf37b402504d13bd1532ee1c
5fe38fa2

Title: Acadia Pharmaceuticals Set to Join S&P SmallCap 600

Source: Yahoo

Published Time: 2024-12-30 22:37:00

URL:

https://finnhub.io/api/news?id=41d1824a2f40917d4988c784ace5d5bccab35af77b8b963166dbd0ab65f20065

Title: Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Source: Yahoo

Published Time: 2024-12-19 21:05:00

URL:

https://finnhub.io/api/news?id=c28e592bd198a181660275444f4c632b04e4d11a2b81a0c44eef218d5526ad81

Title: Acadia Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)

Source: Finnhub

Published Time: 2024-12-17 10:00:52

URL:

https://finnhub.io/api/news?id=8a4307ebe4b8e7d3fe219a34368adb63ea848df743a01f06130c6d713393f63e

Title: Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Source: Yahoo

Published Time: 2024-12-16 21:05:00

URL:

https://finnhub.io/api/news?id=f96aa1d18236ffc7d36f13a95ebce3ffd537466b2a9e1ab340cd4590d09de4bb

Title: High Growth Tech Stocks To Watch In December 2024

Source: Yahoo

Published Time: 2024-12-12 18:03:53

URL:

https://finnhub.io/api/news?id=359488a1f8af7263a60c4ed84ee3612fc93e2e00e19aadec9915f7290625b81e

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders should be happy to see the share price up 19% in the last quarter. But don't envy holders -- looking back over 5 years the returns have been really bad. Indeed, the share price is down 61% in the period. So we're not so sure if the recent bounce should be celebrated. However, in the best case scenario (far from fait accompli), this improved performance might be sustained.

If the past week is anything to go by, investor sentiment for ACADIA Pharmaceuticals isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

View our latest analysis for ACADIA Pharmaceuticals

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

During five years of share price growth, ACADIA Pharmaceuticals moved from a loss to profitability. That would generally be considered a positive, so we are surprised to see the share price is down.

Other metrics may better explain the share price move.

Revenue is actually up 19% over the time period. So it seems one might have to take closer look at the fundamentals to understand why the share price languishes. After all, there may be an opportunity.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

ACADIA Pharmaceuticals is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. So we recommend checking out this free report showing consensus forecasts

ACADIA Pharmaceuticals shareholders are down 43% for the year, but the market itself is up 26%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 10% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. Is ACADIA Pharmaceuticals cheap compared to other companies? These 3 valuation measures might help you decide.

But note: ACADIA Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Sign in to access your portfolio

Published: 2025-01-02 18:00:00 ET

ACAD

ACADIA Pharmaceuticals Inc.(NasdaqGS:ACAD) added to S&P 600 Health Care (Sector)

Published: 2025-01-02 18:00:00 ET

ACAD

ACADIA Pharmaceuticals Inc.(NasdaqGS:ACAD) added to S&P Composite 1500

Published: 2025-01-02 18:00:00 ET

ACAD

ACADIA Pharmaceuticals Inc.(NasdaqGS:ACAD) added to S&P 600

We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

We recently published a list of 10 Firms End 2024 Stronger With Impressive Gains. In this article, we are going to take a look at where ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stands against other firms end 2024 stronger with impressive gains.

A lackluster trading persisted throughout the last day of the year, with Wall Streets main indices ending the day mixed.

The Dow Jones Industrial Average dipped by 0.07 percent, the S&P 500 shed 0.43 percent, and the

Nasdaq Composite declined by 0.90 percent. Meanwhile, NYSE Composite inched up by 0.10 percent and S&P Composite rose by 0.44 percent.

Despite the lack of catalysts to spark trading, 10 companiespredominantly in the biopharmaceuticals sectorposted impressive gains. Lets explore the reasons behind their outstanding performance.

To come up with Mondays top gainers, we considered only the stocks with at least $2 billion in market capitalization and $5 million in daily trading volume.

A research scientist looking through a microscope in a lab, symbolizing the biopharmaceutical company's innovative approach to medical treatments.

Shares in ACADIA Pharmaceuticals (ACAD) increased by 9.95 percent on Wednesday, finishing the year higher at $18.35 apiece following news that it is set to join the S&P SmallCap 600 effective Friday, January 3, 2025, replacing Independent Bank Group Inc.

The S&P 600 is a stock market index tracking the performance of 600 small-cap companies in the US. It is designed to be a reliable benchmark for investors and traders and represents about 3 percent of the US market.

Year-to-date, however, registered a plunge of 40 percent from its valuation a year ago.

Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company specializing in innovative treatments for central nervous system (CNS) disorders including Parkinsons disease psychosis, Alzheimer s-related psychosis, schizophrenia, and Rett syndrome.

It owns NUPLAZID, an FDA-approved treatment for Parkinsons psychosis. Acadias robust research and development pipeline focuses on the growing needs in neurology and psychiatry.

Overall, ACAD ranks 1st on our list of firms end 2024 stronger with impressive gains. While we acknowledge the potential of ACAD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ACAD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock

Disclosure: None. This article is originally published at Insider Monkey.

NEW YORK, Dec. 30, 2024 /PRNewswire/ -- Acadia Pharmaceuticals Inc. (NASD: ACAD) will replace Independent Bank Group Inc. (NASD: IBTX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 3, 2025. S&P MidCap 400 constituent SouthState Corp. (NYSE: SSB) is acquiring Independent Bank Group in a deal expected to close soon pending final conditions.

Following is a summary of the change that will take place prior to the open of trading on the effective date:

Effective Date

Index Name

Action

Company Name

Ticker

GICS Sector

Jan 3, 2025

S&P SmallCap 600

Addition

Acadia Pharmaceuticals

ACAD

Health Care

Jan 3, 2025

S&P SmallCap 600

Deletion

Independent Bank Group

IBTX

Financials

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

FOR MORE INFORMATION:

S&P Dow Jones Indicesindex_services@spglobal.com

Media Inquiriesspdji.comms@spglobal.com

View original content:https://www.prnewswire.com/news-releases/acadia-pharmaceuticals-set-to-join-sp-smallcap-600-302340435.html

SOURCE S&P Dow Jones Indices